Sequence data are available in ENA under project PRJEB31759.

Introduction {#sec001}
============

Travelers' diarrhea (TD) remains a major risk to deployed military forces worldwide, in addition to its impact on civilian travelers and mobile populations \[[@pone.0236703.ref001]\]. As an example of the potential impact on military operations, a study to evaluate health outcomes for U.S. forces deployed to Egypt in 2005 for Operation Bright Star (a biannual exercise with the Egyptian armed forces) revealed that 40% of troops experienced TD during this operation, but only 4% sought formal medical care \[[@pone.0236703.ref002]\]. An anonymous questionnaire of over 15,000 U.S. personnel deployed to Iraq or Afghanistan in 2003--2004 found that 78.6% of troops in Iraq and 54.4% in Afghanistan experienced GI-related illnesses, with 80% seeking care from their unit medic \[[@pone.0236703.ref003]\]. Eating local food from non-U.S. sources was associated with an increased risk of illness \[[@pone.0236703.ref004]\]. Additionally, over 50% of travelers were affected by TD during a two week visit to a developing country \[[@pone.0236703.ref001]\]. Due to their mission-aborting potential, the U.S. military has placed a high priority on the development of effective methods to prevent the most common enteropathogenic diseases \[[@pone.0236703.ref005]\]. Bacterial pathogens, such as enterotoxigenic *Escherichia coli* (ETEC), *Campylobacter jejuni*, and *Shigella* spp. (particularly *S*. *flexneri* and *S*. *sonnei*) are often the most frequent causes of TD in both adults and children, with variability among regions around the world \[[@pone.0236703.ref001],[@pone.0236703.ref005],[@pone.0236703.ref006]\]. However, while common diarrhea-causing pathogens have been implicated in the majority of TD cases, a large proportion of cases have no known cause \[[@pone.0236703.ref006],[@pone.0236703.ref007]\]. The role of the gut microbiome, both in terms of harboring potential TD-causing pathogens and providing either protection or susceptibility to TD, has not been fully explored.

The normal constituents of the human gut microbiome are primarily bacteria, but also include archaea, eukaryotes, and viruses. These microbial cells reach levels of billions per milliliter in the large intestine \[[@pone.0236703.ref008]\]. Each person carries their own personalized mix of different microbes that have been acquired over a lifetime and whose diversity was built up from birth via exposure to family members, food, and other environmental sources \[[@pone.0236703.ref009]\]. Collectively, these microbes are equal to, or outnumber the cells in the human body \[[@pone.0236703.ref010]\], and encode 300 times more genes than the human genome \[[@pone.0236703.ref011]\]. These microbes interact closely with the host immune system \[[@pone.0236703.ref012]\], and they perform critical services for the human host, such as enhanced degradation of dietary components, production of vitamins, degradation of xenobiotics, and protection from pathogen invasion \[[@pone.0236703.ref013]\]. An increasing number of diseases stem from an altered and aberrant microbiome, ranging from inflammatory bowel disease to diabetes \[[@pone.0236703.ref014]\]. There is evidence that the gut microbiome plays a role in TD \[[@pone.0236703.ref015],[@pone.0236703.ref016]\], and that TD can change the gut community structure\[[@pone.0236703.ref017]--[@pone.0236703.ref019]\]. Thus, we hypothesize that gut microbial community composition can be a significant factor in symptomatic and sub-clinical syndromes, and can contribute to susceptibility or resilience to TD.

Gaining a better understanding of how microbial community composition affects military personnel experiencing diarrhea during deployment is important for strategic decisions regarding potential medical interventions, such as use of probiotics as prophylaxis and/or post-infectious therapy. In this study, we initiated a longitudinal cohort surveillance study of 67 individuals that were followed during two 9-month deployment cycles in 2015--2016 to Honduras. After enrollment and collection of baseline samples, subjects were contacted weekly to assess presence of any ailment, including diarrhea and associated symptoms, and if ill, were asked to complete a case report form and submit a stool sample for testing. Additionally, 11 subjects were recruited into a nested substudy to specifically examine gut microbiome composition and changes associated with deployment and illness, with these subjects voluntarily submitting stool samples weekly, regardless of illness, and completing a daily diet, activity, and well-being log.

Materials and methods {#sec002}
=====================

Study site and fieldwork {#sec003}
------------------------

We developed a surveillance site at a forward operating (frontline) military base in Honduras. The base had a population of approximately 600 active-duty and reserve military personnel assigned on one year, six months or 90 day orders. Military personnel were deployed to the site at various times throughout the year on a rolling basis. These individuals frequently arrived as units and remained onsite for the duration of the orders assigned to the unit, and until their replacements arrived. All personnel were prescribed doxycycline for daily use as an antimalarial prophylactic. An on-site medical unit staffed by active duty and reserve personnel and several local Honduras physicians provide year-round medical care to military personnel. While there was a fixed dining facility on base that was monitored frequently for sanitation and food safety, personnel had access to the local economy during their official duties outside the base and when off-duty they were able to visit local towns. TD was defined as three or more loose stools in a 24 hr period. Rates of TD at this location throughout deployment, especially during the first weeks to first month on post, were comparable to rates experienced by military personnel in El Salvador (27%) \[[@pone.0236703.ref020]\] and Peru (24.8%) \[[@pone.0236703.ref021]\].

We implemented two studies to investigate TD during deployment: Study 1 was a passive surveillance study encompassing subjects that reported to the clinic with TD and end-of-deployment questionnaires (N = 1172); and Study 2a was an active surveillance study involving subjects that were recruited for active follow up after they arrived on post (N = 67). The longitudinal microbiome study, where subjects voluntarily supplied weekly fecal samples and entered health and diet information into a daily log, was nested within Study 2a and is termed Study 2b (N = 11). All studies were conducted from February 2014 to November 2016.

### Study 1 {#sec004}

For individuals to be granted Sick in Quarters (SIQ) status when ill they must see a medical provider and provide documentation of their illness to their unit leadership, therefore those reporting to the clinic seeking care often had more severe symptoms. A stool sample was collected for onsite laboratory testing. To capture mild to moderate cases that are typically not reported or captured, we also integrated questionnaires into medical out-processing for all base personnel at the end of each unit's deployment cycle, similar to a prior mid-deployment TD questionnaire-based study \[[@pone.0236703.ref022]\]. The questionnaire is available as [S1 File](#pone.0236703.s002){ref-type="supplementary-material"}. The questionnaires asked about past events including signs and symptoms of diarrhea, respiratory, and febrile illnesses during their deployment, and included questions regarding the impacts of illness on job performance and healthcare seeking outcomes.

### Study 2a {#sec005}

A briefing to explain the study details was performed by non-military study personnel as part of the routine medical in-processing. After a short description of the study, a copy of the consent form was left for individuals to review and if they decided to participate they contacted the study staff individually. There were no exclusion criteria, apart from a requirement of a minimum time on base of one month. Subjects were individually consented to participate in the study and afterwards completed a cohort enrollment form containing questions to collect general demographic data. Potential signs and symptoms of diarrhea and respiratory disease were also captured. The onsite study personnel contacted the subjects once a week by email or by phone to inquire if they have had any diarrhea illness during the last week. If the subject's symptoms met TD definitions, the subject was requested to come to the medical unit and complete a brief case report form regarding their current symptoms. The subject was given a stool collection kit and a stool sample was provided at the subject's convenience and returned to the laboratory for immediate processing and onsite laboratory testing.

### Study 2b {#sec006}

Within the longitudinal cohort design of Study 2a, we also nested a cohort substudy of 11 individuals to specifically examine gut microbiome changes associated with deployment and illness. In addition to the other components of the active cohort study, these 11 subjects voluntarily submitted stool samples weekly regardless of illness, case report forms, stools for every diarrhea episode, and completed a daily diet, activity, and well-being log on an individual Apple iPod, as described below.

This study was jointly approved by the Institutional Review Board at U.S. Naval Medical Research Unit No. 6 (NAMRU-6) in Lima, Peru and 711th Human Performance Wing, Air Force Research Laboratory at Wright Patterson Air Force Base in Ohio. Additionally, the study was approved by both the military base Commander and the regional Medical Officer.

Samples and laboratory analysis {#sec007}
-------------------------------

### 1) Study 1 and 2a {#sec008}

Demographic Data: Subjects were analyzed on the basis of demographic data (rank, sex, branch of service, occupation, deployment duration, travel, vaccinations, preventive medicine guidance, other gastrointestinal disorders, drugs and antibiotics taken, and symptoms within the prior two weeks and at enrollment). Continuous data (e.g. days of decreased job performance) were compared using analysis of variance, followed by individual comparisons using the Bonferroni correction. Differences in distributions of categorical data were compared using the Chi-square test or Fisher's exact test, if Chi-square assumptions were not met.

Incidences of TD were calculated using total time during study participation and the duration of each TD episode. These data, in combination with all laboratory data, were used to calculate incidences for each pathogen. STATA v13 (StataCorp LLC, College Station, TX) was used for analysis of the survey and demographic data.

*Stool analysis*. After self-collection of stools (commode specimen collection system, Fisher Scientific, St. Louis, MO) by subjects, the samples were transported to the laboratory located in the same building as the medical unit and were immediately cultured for bacterial enteropathogens by conventional microbiological techniques \[[@pone.0236703.ref023],[@pone.0236703.ref024]\]. Stool specimens were streaked directly onto xylose lysine deoxycholate (XLD), thiosulfate citrate bile salt sucrose agar (TCBS), MacConkey agar, Salmonella-Shigella agar, and Campylobacter blood agar \[[@pone.0236703.ref025]\]. Inoculated Campylobacter blood agar plates were incubated at 42°C for 48 h in a microaerophilic atmosphere. Bacterial cultures were examined for the following agents at 24, 48, and 72 h for *Salmonella* and *Shigella* spp. Identifications were performed using API-20E identification strips (Biomerieux, Durham, NC, USA). Aliquots of stool samples and all identified stool culture isolates were frozen at -80°C and shipped commercially to U.S. Naval Medical Research Unit No. 6 (NAMRU-6) in Lima, Peru for confirmatory testing. Upon arrival at the laboratory, samples were stored at -80°C until tested. Stool aliquots were fixed in sodium acetate-acetic acid-formalin (SAF) which included 10% formalin (prepared in-house) and were sent to NAMRU-6. These samples were processed for examination for protozoal pathogens (*Entamoeba histolytica*, *Giardia lamblia*, etc) using modified-Trichrome stain of fecal smears, as well as examined for helminth ova by wet mount following concentration of the samples \[[@pone.0236703.ref026]\]. In addition, fecal smears were stained using the modified Kinyoun acid-fast method for the identification of *Cyclospora*, *Cryptosporidium*, and *Isospora*.

Molecular detection of enteropathogens {#sec009}
--------------------------------------

In addition to bacterial culture, all stools from ill subjects were tested using the Biofire FilmArray GI panel (Biofire, Salt Lake City, UT, USA) for detection of the pathogens enteroaggregative *E*. *coli* (EAEC), enteropathogenic *E*. *coli* (EPEC), enterotoxigenic *E*. *coli* (ETEC) lt/st, Shiga-like toxin-producing *E*. *coli* (STEC) stx1/stx2, *E*. *coli* O157, *Shigella*/Enteroinvasive *E*. *coli* (EIEC), *Campylobacter* (*jejuni*, *coli*, and *upsaliensis*), *Clostridium difficile* (toxin A/B), *Plesiomonas shigelloides*, *Salmonella*, *Yersinia enterocolitica*, *Vibrio* (*parahaemolyticus*, *vulnificus*, and *cholerae*), viruses \[Adenovirus F40/41, Astrovirus, Norovirus GI/GII, Rotavirus A, Sapovirus (I, II, IV, and V)\], and parasites \[*Cryptosporidium*, *Cyclospora cayetanensis*, *Entamoeba histolytica*, *Giardia lamblia*\]. Stools were processed and tested on the FilmArray GI panel according to the manufacturer's procedures. Intersecting sets of pathogens were generated via the UpSet analysis tool \[[@pone.0236703.ref027]\].

Study 2b: Microbiome collection, processing, and analyses {#sec010}
---------------------------------------------------------

The subjects (N = 11) provided weekly fecal samples, when possible, on site at the medical unit. Stools were self-collected by subjects utilizing the commode specimen collection system (Fisher Scientific, St. Louis, MO). These were transferred to onsite study personnel where samples were separated into 5 mL aliquots in cryovials and stored at -80°C. Samples were intermittently shipped to Tuebingen, Germany via Wright-Patterson Air Force Base on dry ice. These samples were stored at -80°C until processing. DNA was extracted from these samples using the MagAttract PowerSoil DNA kit (QIAGEN, Hilden, Germany) with the kit's protocol for automated liquid handling systems. Next a two stage PCR process was done to amplify and barcode the hypervariable V4 region of the 16S ribosomal RNA small subunit gene. Briefly, the 515f and 806r primers \[[@pone.0236703.ref028]\] with Nextera Transposase Adapters (Illumina Corp., San Diego, California, USA) were used for PCR amplification at 25 cycles. Then these amplicons then went through an 8 cycle PCR with the Nextera Index primers (using 6 base pair dual barcodes), followed by clean-up using the MagBind PCR clean-up 96 well kit (Omega Biotek). The resulting libraries were sequenced using 250 bp paired-end reads on an Illumina MiSeq system at the Genome Center for the Max Planck Institute for Developmental Biology in Tuebingen, Germany. Negative controls (14 PCR water blanks) and positive control (9 stool samples from the same donor, an individual from the USA) were included and filtered from the final results, as the negative controls had low sequence counts, and did not cluster near adjacent wells in PCoA plots, while the positive controls showed expected behavior (consistent taxonomies and within-subject clustering).

E-survey: To gather self-reported data, the subjects were provided with iPod touch systems (Apple) that had a questionnaire covering diet, daily activities, and self-reported ailments, including self-reported 'gastrointestinal issues'. A spreadsheet of the questionnaire data (manual corrections were done to have consistent date and time format) are available as [S1 Table](#pone.0236703.s005){ref-type="supplementary-material"}. Since a variable number of questionnaire entries could be matched to a weekly stool sample, a custom Python script (described below) was used to match questionnaire data to stool data (i.e., entries from the same day or up to six days prior) and average the data, if any, across that time period to match the stool data.

Sequencing data were processed using the QIIME 2 (2018.8 release) \[[@pone.0236703.ref029]\] and R \[[@pone.0236703.ref030]\] software packages (the R environment is listed in the [S1 Appendix](#pone.0236703.s010){ref-type="supplementary-material"}). A QIIME metadata mapping file is available as [S2 Table](#pone.0236703.s006){ref-type="supplementary-material"}. DADA2 \[[@pone.0236703.ref031]\] was used to process the paired-end reads, and generate sequence variants (SVs) with the following parameters:---p-trim-left-f 19,---p-trim-left-r 20,---p-trunc-len-f 210, and---p-trunc-len-r 210. The SILVA \[[@pone.0236703.ref032]\] 132 release (99% OTUs) was used for taxonomic assignments. Next, taxonomy was filtered out that matched these strings: \'D_0\_\_Eukaryota,D_4\_\_Mitochondria,D_3\_\_Chloroplast\'. The filtered SVs were aligned using MAFFT \[[@pone.0236703.ref033]\] with default parameters, the resulting alignment was filtered using the---p-max-gap-frequency 0.80 parameter, and a phylogenetic tree was inferred using FastTree with midpoint rooting. Samples with less than 4617 sequences were filtered from the data. Beta diversity and alpha diversity were calculated with the default metrics/measures: weighted and unweighted UniFrac, Bray-Curtis, and Jaccard for beta diversity and Chao1, Faith's PD, evenness, shannon, and observed OTUs for alpha diversity \[[@pone.0236703.ref034]--[@pone.0236703.ref038]\]. With specific time points of TD removed, volatility, i.e., fluctuations away from starting values (either alpha diversity values or distances over time for beta diversity) were tested using the QIIME 2 longitudinal plug-in. The "first-differences" function was used in the case of alpha diversity, and "first-distances" was used for beta diversity metrics/measures. Order (see metadata mapping file) was used for the---p-state-column parameter and---p-individual-id-column was Subject. Significance was tested using the "linear-mixed-effects" function of the longitudinal plug-in, with "---p-group-columns SubjectHadTD" as the tested groups.

Linear mixed models for differential abundance were performed using the lmer4 package in R \[[@pone.0236703.ref030],[@pone.0236703.ref039]\]. Specific time points of TD were filtered from the data, and zero-inflation was minimized by filtering out SVs that had less than 1000 sequences or were found in less than 10 samples, leaving 389 SVs. Additionally, subject 34 was removed, as there were only three samples from this subject, and two were filtered (one for low SV count, and the other was a TD time point). The test and null model were:

model \<- lmer(log10(Abundance\^(1/3)+1)\~SubjectHadTD + standardized_counts + (1\|Subject) + (1\|PlateNumber) + Order, data = curr_data, REML = FALSE)

null \<- lmer(log10(Abundance\^(1/3)+1)\~standardized_counts + (1\|Subject) + (1\|PlateNumber) + Order, data = curr_data, REML = FALSE)

where Abundance is the counts of reads, SubjectHadTD is TRUE/FALSE for the subject according to whether any TD incidents occurred, standardized_counts are the sequence counts standardized via the decostand function (using \"standardize\") of the R vegan package \[[@pone.0236703.ref040]\], the Subject is the participant, PlateNumber is the plate that the samples were processed on, and Order is the sample order.

The test and null model were compared with the R anova test, to determine if the test model fit the data significantly better than the null model. Only the SVs with residual histograms and Q-Q plots that reflected normality were reported as significant in [S3 Table](#pone.0236703.s007){ref-type="supplementary-material"}. Differential alpha diversity values were tested in a similar manner (for Chao1, ObsOTUs, PD, and Shannon metrics) for TD+ versus TD- subjects, with the average alpha diversity value for 10x rarefactions at 4617 sequences/sample used instead of SV Abundance values (no data transformation necessary for normality). To compare self-reported iPod questionnaire data to microbiome data, first the (up to daily) entries had to be related to a collected fecal sample (up to weekly). To do this, data were converted into quantitative form (e.g., a "true" entry for GI distress becomes 1, "false" becomes 0) and the data were averaged for the day of the fecal sample and the six prior days. The custom Python script is available on gisthub (<https://gist.github.com/walterst/ca4a41d32cceba809c77b55fc2c068cc>). The QIIME-formatted metadata mapping file, [S2 Table](#pone.0236703.s006){ref-type="supplementary-material"}, includes the parsed data from the iPod questionnaire. Because not all samples have associated iPod questionnaire data (137 of 215 samples had iPod data in range, see MatchingIPodData field in [S2 Table](#pone.0236703.s006){ref-type="supplementary-material"}), samples lacking data had to be filtered before further testing. A linear mixed model was applied in a similar fashion to the categorical tests for SVs, above, for self-reported Gastrointestinal issues across all SVs:

model \<- lmer(log(Abundance\^(1/6)+1)\~Gastrointestinal_issues + standardized_counts + (1\|Subject) + (1\|PlateNumber) + Order, data = curr_data, REML = FALSE)

df.null \<- lmer(log(Abundance\^(1/6)+1)\~standardized_counts + (1\|Subject) + (1\|PlateNumber) + Order, data = curr_data, REML = FALSE)

where Gastrointestinal_issues is the self-reported GI distress values from the iPod questionnaire, while other variables are as described in the above section for differential abundance. A total of five SVs had p-values \< 0.05 after FDR (False Discovery Rate, Benjamini-Hochberg), but only the two SVs had residual histograms and Q-Q plots that reflected normality are reported on [S3 Table](#pone.0236703.s007){ref-type="supplementary-material"}. Significance after FDR correction, for stool consistency and time slept, was not detected.

To compare the clustering of the subjects in this study with geographically distinct subjects, the V4 16S ribosomal RNA small subunit amplicon sequence data from a global gut survey \[[@pone.0236703.ref041]\] were randomly subsampled to 3% of the total reads, which approximates an Illumina MiSeq run at \~30000 reads/sample. The random subsampling Python script is available on gisthub (<https://gist.github.com/walterst/22c9fb9d1f817eae55c14a84b1b106d9>). As the sequences were not the same lengths and were generated with different sequencing technologies (making a sequence variants approach inappropriate), the read data for both the Yatsunenko study and the reads for the TD subjects were clustered in a "closed-reference" approach, at 97% identity, against the SILVA 132 97% OTUs. Beta diversity was calculated with the weighted UniFrac metric at an even sampling of 4257 sequences per sample. Samples were filtered so that only adult subjects were retained. The combined mapping file for the TD subjects and the subjects from the Yatsunenko study is available as [S4 Table](#pone.0236703.s008){ref-type="supplementary-material"}.

The Firmicutes:Bacteroidetes ratio was calculated by first averaging each individual subject's Firmicutes and Bacteroidetes relative abundances (with TD time points removed) as a per-subject average, then averaging the TD+ versus TD- subject averages.

Sequence data are available in ENA under project PRJEB31759.

Results {#sec011}
=======

Epidemiology studies {#sec012}
--------------------

A total of 1,172 individuals completed the questionnaires from 2014--2016 as part of study 1. The majority of the personnel completing the questionnaires were male (82.6%) with a mean age of 32.7 (32.3, 33.3, 95% CI) years for all subjects. The mean age of female subjects was slightly older (33.5 years) than males (32.7 years, [Table 1](#pone.0236703.t001){ref-type="table"}). Reporting of military rank showed the majority of subjects were enlisted personnel (71.8%). The majority of the personnel deployed to this site were reserve forces, whereas the command leadership was primarily active duty. In review of the occupations most of the subjects were medical personnel (not shown). Of those completing the questionnaires, 293/1173 (25.0%) reported experiencing TD during their deployment, with a median of two episodes per person reported with each episode lasting a median of two days ([Table 2](#pone.0236703.t002){ref-type="table"}). Additionally, 48.3% reported experiencing moderately severe TD defined at 3--5 stools per 24h period, 42.9% reported severe TD defined as greater than or equal to six stools per 24h period, and only 8.4% with mild TD defined as 1--2 stools per 24h period. For duty days lost, 78.8% subjects who completed the questionnaires reported no time lost ([Table 2](#pone.0236703.t002){ref-type="table"}). However, 57.6% reported experiencing a reduction in their ability to perform their job from their illness, ranging from 1--60 days. For questions that asked about care-seeking behaviors associated with illness, 38.7% reported to urgent care (sick call) at the clinic and 15.2% reported being in a Sick in Quarters (SIQ) status and unable to work ([Table 2](#pone.0236703.t002){ref-type="table"}). Similarly, 22.1% reported taking antibiotics as a treatment for illness, although we were not able to determine whether the prescription was given at the clinic or prior to deployment from their travel medicine clinicians and self-administered. It should be noted that all subjects were mandated to take doxycycline as an antimalarial prophylactic during deployment. Only 9.4% reported needing intravenous (IV) fluids during their clinical care. We collected data on symptoms associated with TD during deployment, including those experiencing nausea (35.8%), vomiting (14.8%), fever (28.2%), bloody diarrhea (4.9%), headache (33.3%), abdominal cramps (58.1%), and joint or muscle aches (28.2%) ([Table 3](#pone.0236703.t003){ref-type="table"}).

10.1371/journal.pone.0236703.t001

###### Post deployment questionnaire demographics.

![](pone.0236703.t001){#pone.0236703.t001g}

  Subjects   n                                           Mean age (95% CI)
  ---------- ------------------------------------------- -------------------
  Female     203 (17.4%)                                 33.5 (32.3, 34.7)
  Male       965 (82.6%)                                 32.7 (32.2, 33.2)
  Enlisted   842 (71.8%)                                 
  Officer    329 (28.1%)                                 
  Total      1172[\*](#t001fn001){ref-type="table-fn"}   32.8 (32.3, 33.3)

\*33 individuals did not report Gender

10.1371/journal.pone.0236703.t002

###### Post deployment questionnaire, impact of diarrhea.

![](pone.0236703.t002){#pone.0236703.t002g}

  Variable (number of respondents)   Result                                    n (%)
  ---------------------------------- ----------------------------------------- -------------
  Diarrhea (1172)                    Yes                                       293 (25.0%)
                                     No                                        879 (75.0%)
                                     Median episode \# per person (min, max)   2 (1, 40)
  Stools/24 h (443)                  Mild (1--2 stools)                        37 (8.4%)
                                     Moderate (3--5 stools)                    214 (48.3%)
                                     Severe (\>6 stools)                       190 (42.9%)
  Days experiencing diarrhea (445)   Median per person (min, max)              3 (1, 60)
  Duty days lost (448)               0 days                                    353 (78.8%)
                                     1--2 days                                 81 (18.1%)
                                     3--40 days                                14 (3.1%)
  Days reduced performance (448)     0 days                                    190 (42.4%)
                                     1--5 days                                 234 (52.2%)
                                     \>5 days                                  24 (5.4%)
  Clinical follow up (447)           Sick call                                 173 (38.7%)
                                     Sick in quarters                          68 (15.2%)
                                     Intravenous fluid                         42 (9.4%)
                                     Antibiotic                                99 (22.1%)

10.1371/journal.pone.0236703.t003

###### Symptoms associated with diarrhea.

![](pone.0236703.t003){#pone.0236703.t003g}

  n = 445              Yes           No
  -------------------- ------------- -------------
  Nausea               160 (35.8%)   287 (64.2%)
  Vomiting             66 (14.8%)    379 (85.2%)
  Fever                126 (28.2%)   321 (71.8%)
  Bloody diarrhea      22 (4.9%)     136 (95.1%)
  Headache             149 (33.3%)   298 (66.7%)
  Abdominal cramps     259 (58.1%)   187 (41.9%)
  Joint/muscle aches   126 (28.2%)   321 (72.8%)

\*Not all questions received responses and had missing data

Through the period of February 2014 through November 2016, 152 subjects reported to the clinic with complaints of diarrhea and were enrolled in the passive surveillance study. These subjects completed a case report and provided a stool for laboratory workup. Stool culture detected 2 cases of *Shigella* and 1 case of *Salmonella* infections while an *ad hoc* ova and parasite exam did not find any cases of protozoan or helminth infections among those enrolled ([Table 4](#pone.0236703.t004){ref-type="table"}). However, implementation of Biofire FilmArray GI assays detected pathogens in 90.8% of cases ([Table 4](#pone.0236703.t004){ref-type="table"}), of which 41.4% had multiple pathogens detected. This culture-independent detection provided information on TD that had not been captured among deployed military personnel previously. Our findings showed that diarrheagenic *E*. *coli* pathogens were predominant at this site, with EAEC as the most common (34.2%), followed by ETEC (32.9%), EPEC (23.0%), and STEC (13.2%). *Shigella* was detected in 18 cases (11.8%) compared to only 2 cases (1.3%) found by bacterial culture, highlighting the increased sensitivity of the non-culture base FilmArray method. Other pathogens detected included norovirus (7.9%), *Cryptosporidium* (4.6%), *Campylobacter* species (3.3%), *Cyclospora* (2.0%), *Clostridium difficile* (2.0%), and one case each of *Yersinia enterocolitica* and rotavirus. These findings show the complexity of TD among deployed military personnel and highlight the challenges in prevention and treatment efforts for multi-microbial infections of bacterial, viral, and protozoan pathogens.

10.1371/journal.pone.0236703.t004

###### Study 1 Laboratory results. O & P indicates ova and parasites.

![](pone.0236703.t004){#pone.0236703.t004g}

  Method      Result                      n     \%
  ----------- --------------------------- ----- ------
  Culture     *Shigella*                  2     1.3
              *Salmonella*                1     0.7
  O & P       Negative                    152   100
  FilmArray   EAEC                        52    34.2
              ETEC                        50    32.9
              EPEC                        35    23.0
              STEC                        20    13.2
              *Shigella*/EIEC             18    11.8
              Norovirus                   12    7.9
              *Cryptosporidium*           7     4.6
              *Campylobacter*             5     3.3
              *Cyclospora*                3     2.0
              *Clostridium difficile*     3     2.0
              *Yersinia enterocolitica*   1     0.7
              Rotavirus                   1     0.7
              Multiple pathogen (2--6)    63    41.4
              Total Positive              138   90.8
              Total                       152   

EAEC: enteroaggregative E. coli, EPEC: enteropathogenic E. coli, ETEC: enterotoxigenic E. coli, STEC: Shiga-like toxin producing E. coli, EIEC: Enteroinvasive E. coli.

To better understand the risk and impact of TD at the military base, we also conducted an active surveillance study (study 2a) in tandem with the passive surveillance (study 1) and post-deployment questionnaires. The study was a longitudinal cohort design with subjects recruited at the start of their deployment. In this study, we were able to recruit 67 total subjects over two deployment cycles from 2015--2016. The majority of subjects were males (74.6%) with a mean age of 37.6 years ([Table 5](#pone.0236703.t005){ref-type="table"}). Analysis of data collected from subjects at the time of enrollment showed no significant trends or associations. Of note, 100% of those enrolled lived on-base for the study, 57% noted traveled in the month prior, and 5/67 (7.7%) noted experiencing diarrhea and/or vomiting in the previous two weeks with 4/67 (6.0%) reporting diarrhea at the time of enrollment. Additionally, 55/65 (84.6%) reported taking an antibiotic, of which doxycycline or another antimalarial drug was listed. The total time the population was at risk was 568.8 person-months and during this time 17 episodes of diarrhea were reported to the study coordinator for an incidence rate of 2.99 cases per person-month ([Table 6](#pone.0236703.t006){ref-type="table"}). For comparison, 11 cases of respiratory disease were detected for an incidence rate of 1.93 cases per person-month. Upon reporting of a case of diarrhea, subjects were asked questions regarding specific risk factors including drinking tap water and eating at alternative locations such as restaurants, hotels, and street vendors but due to the small sample sizes no significant associations with illness were found. Of the 17 diarrheal events, 16 stool samples were submitted for laboratory workup. *Shigella* was found in only one case, by bacterial culture, with no protozoa or helminths detected ([Table 7](#pone.0236703.t007){ref-type="table"}). The FilmArray GI panel was positive for 12/16 (75.0%) of samples tested with 9/16 found to have multiple pathogens. Similar to the findings from our passive surveillance cases, diarrheagenic *E*. *coli* pathogens were most predominant with EAEC and EPEC as the most common (43.8% equally), followed by ETEC (37.5%), and STEC (18.8%). Other pathogens detected included rotavirus, *Cyclospora*, and *Campylobacter* ([Table 7](#pone.0236703.t007){ref-type="table"}). Co-infections predominated (\~63% of cases, [Fig 1](#pone.0236703.g001){ref-type="fig"}). While pathogens were detected as mono-infections, a majority of the time, each pathogen was detected as a co-infection with one or more of the diarrheagenic *E*. *coli* strains. This includes the *E*. *coli* strains themselves---for example, ETEC was detected alone in 15 cases, but it was detected alongside another *E*. *coli* strain in 40 cases.

![Intersections of pathogen infections across the study 1 and 2 cohorts.\
Pathogens are shown on the lower left, with the size of the horizontal bars indicating the frequency of the pathogen incidents across the data set. The vertical bar charts indicate the sorted counts of each set interaction, with the bottom dots and connecting lines indicating detection of a pathogen and its co-occurrence with other pathogens, e.g., ETEC occurred alone 15 times, EPEC and EAEC were a co-infection 10 times, and so on. Co-infections were quite prevalent, with rare cases of predominantly singly-infectious agents, such as Cyclospora (detected three times alone, once as a co-infection with ETEC).](pone.0236703.g001){#pone.0236703.g001}

10.1371/journal.pone.0236703.t005

###### Study 2a cohort demographics.

![](pone.0236703.t005){#pone.0236703.t005g}

  Subjects   n            Mean age (95% CI)
  ---------- ------------ -------------------
  Female     17 (25.4%)   42.2 (36.9, 47.6)
  Male       50 (74.6%)   37.6 (34.7, 40.5)
  Total      67           

10.1371/journal.pone.0236703.t006

###### Study 2a diarrheal incidence.

![](pone.0236703.t006){#pone.0236703.t006g}

  Variable            
  ------------------- -----------------------------------------
  Time at risk        568.8 person months
  Diarrhea episodes   17[\*](#t006fn001){ref-type="table-fn"}
  Incidence rate      2.99 per 100 person months

\*Only 16 samples received for laboratory testing

10.1371/journal.pone.0236703.t007

###### Study 2 laboratory results. O & P indicates ova and parasites.

![](pone.0236703.t007){#pone.0236703.t007g}

  Method      Result                     n    \%
  ----------- -------------------------- ---- ------
  Culture     *Shigella*                 1    6.3
  O & P       Negative                   16   100
  FilmArray   EPEC                       7    43.8
              EAEC                       7    43.8
              ETEC                       6    37.5
              STEC                       3    18.8
              *Campylobacter*            1    6.3
              *Cyclospora*               1    6.3
              Rotavirus                  1    6.3
              Multiple pathogen (2--6)   9    56.3
              Total Positive             12   75.0
  Total       16                              

EAEC: enteroaggregative *E*. *coli*, EPEC: enteropathogenic *E*. *coli*, ETEC: enterotoxigenic *E*. *coli*, STEC: Shiga-like toxin producing *E*. *coli*, EIEC: Enteroinvasive *E*. *coli*.

Microbiome changes were associated with deployment and TD events {#sec013}
----------------------------------------------------------------

The 11 subjects recruited into the microbiome cohort had an average age of 36.3 (23.7, 48.9; 95% CI), with deployments ranging from 147--466 days ([Table 8](#pone.0236703.t008){ref-type="table"}). Four experienced diarrhea, with two of these subjects testing positive for enteric pathogens on the Biofire array assay.

10.1371/journal.pone.0236703.t008

###### Nested cohort (Study 2b), demographics and summary of diarrheal incidents and clinical results.

![](pone.0236703.t008){#pone.0236703.t008g}

  Subject   Age   Sex   time at risk (days)   time at risk (months)   episodes diarrhea   Pathogens
  --------- ----- ----- --------------------- ----------------------- ------------------- ------------------------------
  020       20    M     147                   4.9                     0                   N/A
  022       21    M     148                   4.93                    0                   N/A
  023       32    M     144                   4.8                     0                   N/A
  024       34    M     157                   5.23                    0                   N/A
  025       30    M     158                   5.27                    0                   N/A
  029       47    F     149                   4.97                    4                   EPEC/ ETEC/ EAEC/Cyclospora
  033       33    M     146                   4.87                    2                   EAEC/ETEC/ STEC/ E.coli 0157
  034       50    M     147                   4.9                     1                   Not detected
  035       56    F     154                   5.13                    0                   N/A
  041       NA    NA    466                   15.53                   0                   N/A
  043       40    M     365                   12.17                   1                   Not detected

Fecal 16S ribosomal RNA small subunit hypervariable region V4 amplicons were grouped into identical sequence variants (SVs). The relative abundance of the dominant phyla, derived from these SVs, arranged according to sampling week and with incidents of TD or self-reported GI distress, are shown in [Fig 2](#pone.0236703.g002){ref-type="fig"}. There is sparsity in the week to week voluntary sampling, and variability in the number of samples provided by subject, however, there are trends and observations of interest. In general, subjects had their own microbial signature that remained mostly consistent over time. Fluctuations in certain taxa do not appear to be related to TD or GI distress events, e.g., Actinobacteria increases substantially in relative abundance for subjects 20, 22, and 33, without any apparent relationship to TD, and subject 23 is dominated in late (week 30+) time points with Archaea (*Methanobrevibacter smithii*) with no reported clinical disease (self-reported data were not available from this subject in later weeks). Proteobacteria blooms were present in most time points of TD, but were also found in many samples with no TD. Subject 41, who reported many cases of GI distress, had frequent blooms of Proteobacteria, but these did not appear to be linked to individual reports of GI distress. Most of the Proteobacteria detected was Gammaproteobacteria (*Escherichia-Shigella* spp.), particularly in, but not limited to, the time points of TD. Subject 34 had a bloom of Alphaproteobacteria (Rhizobiales) during the TD time point. This same taxa bloomed in non-TD time points for both subjects 24 and 25, so this taxa is not necessarily indicative of TD. There are Pasteurellales and Pseudomonadales detected in some Proteobacteria blooms, but these are not associated with TD events. The taxonomy plots can be viewed at various depths of taxonomy and with available metadata included with the QIIME2 visualization artifact ([S2 File](#pone.0236703.s003){ref-type="supplementary-material"}, visualize at <https://view.qiime2.org/>, see [S2 File](#pone.0236703.s003){ref-type="supplementary-material"} text).

![Study 2b Microbial phyla over time for all subjects.\
The relative abundance of the most abundant phyla are shown for each subject along with the weekly time points where samples were collected. Week 1 indicates the first week of deployment overseas. TD events are indicated with a gold star and self-reported GI distress is indicated by blue stars.](pone.0236703.g002){#pone.0236703.g002}

To better understand the interactions between the gut microbiome and TD, we focused on the two subjects that had the most frequent clinical visits because of TD. Subjects, 29 and 33, had recurring (in this case, incidents that spanned more than one of our weekly samples) TD. Subject 29 is the only subject in this study to report having TD prior to enrollment, but had a negative result for the first stool submitted The subject was positive for EPEC/ETEC in the second stool submitted 13 days later, EPEC/ETEC/EAEC for the third stool submitted 30 days later, and ETEC/Cyclospora for fourth stool submitted after an additional 14 days. Subject 33 was positive for EAEC/ETEC/STEC in both stools submitted 15 days apart. The most abundant microbial families are shown by sampling week for subject 29 in [Fig 3](#pone.0236703.g003){ref-type="fig"}. In accordance with *Escherichia* spp. infection, there was a large overgrowth of *Enterobacteriaceae* during most of the weeks with TD incidents. Week 14 is the notable exception: during this week, a eukaryotic pathogen was detected (*Cyclospora cayetanensis*, via parasitology tests). *Bacteroidaceae*, *Rikenellaceae*, and *Ruminococcaceae* were substantially reduced during infections, while the relative abundance of *Lachnospiraceae* and *Veillonellaceae* increased. Unrelated to any apparent clinical or self-reported GI issues, there was a large bloom of Clostridiales Family XIII in week three, which was detectable but much lower in abundance during other weeks. Subject 33's bacterial families are shown in [Fig 4](#pone.0236703.g004){ref-type="fig"} by sampling week. This subject experienced *Escherichia* spp. infection on weeks 15 and 17, but an *Enterobacteriaceae* bloom can be seen in the weeks preceding and following the TD events. In this subject, TD was associated with a loss of *Bacteroidaceae* and the archaea *Methanobacteriaceae*, and an increased relative abundance of *Akkermansiaceae*. Week 30 also shows a bloom of *Enterobacteriaceae*, but in this case, the surrounding weeks lack the bloom or shifts in other taxa observed for the prior TD events. There was no clinical or self-reported GI distress for this week, indicating that this bloom was not sufficient to cause debilitation to this subject. Additionally, later weeks showed an increased abundance of *Bacteroidaceae* family, while many Firmicutes and *Methanobacteriaceae* decreased, with no apparent health effects. We should be careful to note that these microbial shifts could simply be indicative of TD, rather than causative (e.g., *Akkermansiaceae* may seemingly be increased in stool abundance due to TD-related sloughing of epithelial cells).

![Family level taxa over time for Subject 29.\
Time series of family-level taxa for a subject experiencing multiple episodes of TD. Subject 29 is shown with taxa from the ten most abundant bacterial families for this subject, with the remaining bacteria and archaea collapsed into a single category.](pone.0236703.g003){#pone.0236703.g003}

![Family level taxa over time for Subject 33.\
Shifts in family-level taxa for subject 33, who experienced multiple episodes of TD. Taxa are shown from the ten most abundant families for this subject, with the remaining bacteria collapsed into a single category.](pone.0236703.g004){#pone.0236703.g004}

Differences in abundances of particular taxa could indicate TD resistance or susceptibility. Using a linear mixed model, to account for the non-independence of longitudinal subject data, differentially abundant SVs were detected after false discovery rate correction, between the subjects who experienced clinically diagnosed TD versus those who did not (these calculations include all time points before and after TD for the subjects, with the specific time points of TD removed). These SVs were both classified to the *Ruminococcaceae* family, with a *Ruminococcaceae* UCG-013 SV more abundant in TD+ subjects, while a *Ruminiclostridium* sp. SV had higher relative abundance in TD- subjects ([Fig 5](#pone.0236703.g005){ref-type="fig"}, [S3 Table](#pone.0236703.s007){ref-type="supplementary-material"}). These taxa may play a role in susceptibility to or protection from TD.

![SVs differentially abundant based upon traveler\'s diarrhea status.\
Two SVs showed differential abundance with a linear mixed model approach and after FDR correction for TD+ vs TD- subjects. The relative abundance of each are shown, separated by subjects who experienced TD versus those who did not (specific time points of TD incidents are not included). The most specific taxonomic classification for the sequence variant is shown; *Ruminococcaceae* UCG-013 in A (p-value 0.0053), and a *Ruminiclostridium* spp. in B (p-value 0.040). The p-values are FDR corrected.](pone.0236703.g005){#pone.0236703.g005}

Using a similar approach, continuous data from self-reported GI distress (with higher values indicating more frequent logging of GI distress with the daily iPod questionnaire) were tested for correlations to the relative abundances of SVs using a linear mixed model. Two SVs, after meeting normality assumptions and FDR (Benjamini-Hochberg) correction, were shown to have a positive relationship with GI distress ([S3 Table](#pone.0236703.s007){ref-type="supplementary-material"}). One is a Gammaproteobacteria, a *Haemophilus* sp. (slope 1.77, FDR corrected p-value 0.0007), and the other is *Turicibacter* sp. (slope 1.57, FDR corrected p-value 0.016), in the Firmicutes phylum. We also examined self-reported stool consistency. We noticed that the Pseudomonadales and Rhizobiales bloom (in the non-TD time points) described earlier had self-reported stools that were harder than the subject's average. However, these data were only a handful of time points, and no taxa were significantly associated with stool consistency using linear mixed model testing.

Alpha diversity differences between TD+ and TD- subjects were tested for via a linear mixed model as described for differential SV abundances. No differences were detected with multiple metrics. Longitudinal differences between the TD- and TD+ groups for alpha and beta diversity measures/metrics was tested with the QIIME2 longitudinal plug-in; no significant results were detected ([S1 Fig](#pone.0236703.s001){ref-type="supplementary-material"}).

The samples in our cohort of subjects deployed to Honduras were compared to subjects from a global fecal survey \[[@pone.0236703.ref041]\], which included individuals from the USA, Venezuela, and Malawi. Our cohort clustered closely to the USA adult population with a weighted UniFrac metric ([Fig 6A](#pone.0236703.g006){ref-type="fig"}, [S3 File](#pone.0236703.s004){ref-type="supplementary-material"}, see [S3 File](#pone.0236703.s004){ref-type="supplementary-material"} text). Interestingly, there did not appear to be any divergence over time away from this initial clustering of samples, indicating general stability in the microbiome for this group deployed from the USA for a prolonged period to Honduras ([Fig 6B](#pone.0236703.g006){ref-type="fig"}). Based upon self-reported diet data, these subjects mostly consumed food and water provided at the base rather than local venues, limiting potential microbial colonization and shifting of these subjects' microbiome. Subjects clustered with themselves over time ([Fig 6C](#pone.0236703.g006){ref-type="fig"}), as expected, and the particular time points of TD did not show a strong divergence from the subjects' other time points ([Fig 6D](#pone.0236703.g006){ref-type="fig"}).

![PCoA of study 2b subjects deployed to Honduras.\
Samples are shown in a principal coordinate plot, clustered by weighted UniFrac distances, with the axis numbers showing the percentage variation explained by that axis. A) Samples from the current study compared to samples from other locations (Yatsunenko et al \[[@pone.0236703.ref041]\]). Samples are colorized by geographic location. B) Samples from the study 2b are shown in a time gradient (week of sampling; week 1 indicates the first week of overseas deployment). C) All samples from each subject in study 2b are colorized by individual. D) The specific time points of TD incidents in the study 2b are highlighted. See also [S2 File](#pone.0236703.s003){ref-type="supplementary-material"}.](pone.0236703.g006){#pone.0236703.g006}

We detected a higher Firmicutes:Bacteroidetes ratio in subjects who did not get TD, with an average of 2.08 Firmicutes:Bacteroidetes for TD- subjects versus 1.64 for TD+ subjects (Firmicutes/Bacteroidetes fractional abundance of 0.571±0.115/0.274±0.128 for TD- subjects, and 0.522±0.073/0.318±0.162 for TD+ subjects, with standard deviation shown). This is consistent with a prior observation for subjects affected by, or resistant to, TD \[[@pone.0236703.ref019]\]. If this pattern can be confirmed with larger sample sizes, it may suggest differential resistance, i.e., the host\'s microbial community occupies niches and prevent TD-causing microbes from successfully colonizing the host, or resilience to TD-causing microbes, in which case the host\'s microbes can be disrupted but rebound quickly and limit the effects of TD.

Discussion {#sec014}
==========

Utilizing questionnaire data from over 1000 subjects deployed to a forward operating base in Honduras, we confirmed that travelers' diarrhea (TD) is a persistent issue even in a location that has modern facilities and a relatively slow pace of operations. Of those people experiencing TD during their deployment, the majority reported greater than three stools per 24-hour period, resulting in reduced performance. From our passive and active surveillance studies (Studies 1 and 2a), the majority of TD cases had multiple pathogens associated with each episode, with diarrheagenic *E*. *coli* strains common in many of the cases. TD in deployed personnel was shown to have a complex etiology, which has implications for its prevention and treatment. It is important to note that the rate of TD was much lower in this study than rates reported in other frontline bases and could be reflective of the more modern facilities, predominantly onsite dining, and lower pace of operations compared to other locations. It is also important to note that this is the clinical incidence of TD, so there may have been cases of mild TD that were not captured. Similarly, questionnaires performed at the end of a person's deployment may not accurately capture what they actually experienced because of recall bias. Additionally, we were not able to recruit and enroll subjects prior to their arrival at the military base, so recruitment frequently occurred in the second or third week after the personnel had arrived and been processed on site. Considering these constraints, it is likely the actual incidence rate of diarrhea among this population is much higher than reported here.

The role of the gut microbiome in TD is beginning to be explored. Pop and colleagues \[[@pone.0236703.ref015]\] simulated TD by inoculating volunteers (from the USA) with ETEC strain H10407, and tested for differences in the microbiomes of those who acquired TD versus those who were resistant. Youmans, et al. \[[@pone.0236703.ref019]\] observed samples of subjects within 72 hours of TD incidents, finding that the healthy travelers (N = 12) and TD subjects (N = 99) clustered distinctly (inter-subject differences, beta diversity), but the healthy travelers had a higher Firmicutes:Bacteroidetes ratio. We also observe a higher Firmicutes:Bacteroidetes ratio in our TD- subjects relative to the TD+ individuals. Although a number of taxa were differentially abundant between the two groups (described previously), there was no difference in intra-subject diversity (alpha diversity) with healthy controls. Similarly, no intra-subject diversity (alpha diversity) differences were found in the pre-travel samples of healthy and TD subjects in a cohort of 43 individuals that were sampled before and after traveling to tropical locations worldwide \[[@pone.0236703.ref016]\]. Our results are consistent with these prior observations, as we detect no differences for alpha diversity between TD+ and TD- subjects. It should be emphasized that while our results are not statistically significant, the number of independent samples are small (N = 4 TD- subjects, N = 7 TD+ subjects).

Microbial taxonomies associated with the subjects who acquired TD versus those that did not for these three studies are shown in [S5 Table](#pone.0236703.s009){ref-type="supplementary-material"}. There is modest overlap between their results, and *Prevotella copri* showed opposite effects---however, it should be noted that both the sampling and statistical methodology are different among these three studies. There could be particular strains of *P*. *copri* providing differential susceptibility or protection, and this group could behave differently depending upon the context of the population. For example, children with higher abundance of *P*. *copri* in developing countries tend to be protected from diarrhea \[[@pone.0236703.ref017]\]. In an extensive longitudinal study of two subjects \[[@pone.0236703.ref042]\], changes in the microbial community were detected during episodes of diarrheal illness, and the community maintained an altered stable state in one subject even after recovery; the long-term impacts of altered gut microbiota on host health following TD are unexplored. In *Campylobacter* spp. specific studies of TD and its relationship to the microbiome, taxa of the Firmicutes phylum were noted to be in increased relative abundance in subjects protected from infection. Kampmann and colleagues showed enrichment of the Lachnospiraceae family (*Dorea* and *Coprococcus* genera) \[[@pone.0236703.ref043]\] was found in subjects that did not acquire *Campylobacter* spp.-causing TD. Dicksved et al showed that the Clostridiales order was enriched in subjects that did not become infected with *Campylobacter* spp. \[[@pone.0236703.ref044]\] in particular, Lachnospiraceae (unclassified) and the *Anaerovorax* genera. Lower relative abundance of the Bacteroidetes phylum, and species in the *Escherichia*, *Phascolarctobacterium*, and *Streptococcus* genera, was observed in these subjects. We did not observe TD-causing *Campylobacter* spp. in our study, and thus these prior results may not be directly applicable to our observations, however, there could be a general mechanism, such as niche occupation and resistance to depletion by particular Firmicutes for microbiome-derived TD resistance.

In this study, we detected bacteria that were differentially abundant in healthy subjects versus those that contracted TD. These were both taxa within the *Ruminococcaceae* family, and they may play a role in providing protection (*Ruminiclostridium* sp.) or susceptibility to TD (*Ruminococcaceae* UCG-013). *Ruminiclostridium* can produce short-chain fatty acids \[[@pone.0236703.ref045]\] that aid in epithelial integrity, which could explain its protective effect observed in this study. Limited information about the uncultured *Ruminococcaceae* UCG-013 group is available in regards to GI diseases, however, a customized diet intervention to mitigate the effects of inflammatory bowel disease caused a depletion of *Ruminococcaceae* UCG-013 \[[@pone.0236703.ref046]\], indicating a potential role in GI health. The few prior studies of TD showed limited overlap with our results, or each other, but *Ruminococcaceae* had taxa that both exacerbated and protected from TD \[[@pone.0236703.ref015],[@pone.0236703.ref016]\]. Our results did not show differences in alpha diversity of the TD+ and TD- subjects, which replicates prior observations \[[@pone.0236703.ref016],[@pone.0236703.ref019]\]. We tested the hypothesis that a microbiome that was volatile (either in overall, or alpha diversity, or shifting in membership, beta diversity) was more susceptible to TD, however, we did not detect significant differences to support this notion. Nevertheless, we did qualitatively observe disruptions to the microbiome in time points prior to actual TD events for a subject with recurrent TD. Taxa associated with self-reported GI distress were also detected (*Haemophilus* and *Turicibacter* spp.). *Haemophilus* spp. have been associated with diarrheal disease \[[@pone.0236703.ref045]\], while the *Turicibacter* sp. is more difficult to explain---the depletion of this taxa was detected in irritable bowel syndrome patients \[[@pone.0236703.ref046]\], showing a potentially contradictory role to our self-reported GI distress subjects.

Multiple studies have been conducted to assess the incidence, etiology, and immediate impact on health and military readiness due to TD \[[@pone.0236703.ref002],[@pone.0236703.ref004],[@pone.0236703.ref047]--[@pone.0236703.ref049]\]; however, much less focus has been given to possible persistent symptoms and diminished quality of life in the aftermath of these acute syndromes, which may result in a significant burden of disease among returning veterans \[[@pone.0236703.ref020]\]. The potential of these pathogens to cause continued sequelae beyond the duration of deployment may be difficult to detect, especially for National Guard and Army Reserve personnel who return to civilian lives and are not frequently followed by the Military Health System \[[@pone.0236703.ref021]\]. Post-infectious irritable bowel syndrome (PI-IBS) is one of the major concerns following GI disease in military personnel. PI-IBS is a constellation of functional gastrointestinal symptoms which occur and persist following the resolution of TD. Two recent meta-analyses showed a 7--8 fold increase in relative risk for IBS following primary infection compared with healthy controls \[[@pone.0236703.ref050],[@pone.0236703.ref051]\]. This risk appears to remain elevated at 24--36 months after infection \[[@pone.0236703.ref050]\]. In addition, recent metagenomics have demonstrated that changes in anaerobic gut bacteria (shifts from beneficial Bacteriodetes phyla to potentially harmful species of the Firmicutes phyla, specifically those from the Clostridiales family) correlate with cases of inflammatory bowel disease and irritable bowel syndrome (including PI-IBS) relative to the gut microbial community of healthy persons \[[@pone.0236703.ref051]--[@pone.0236703.ref056]\]. These microbial community changes may result in increased gas production by bacteria, decreased immune tolerance, increased inflammation of the gut, and reduced gut-absorption, all of which correlate to the symptoms of IBD and IBS \[[@pone.0236703.ref051]\]. Long term changes (i.e. weeks or months after a TD incident) in an individual's stool microbiome were not observed in our study after a TD episode, with their microbial community generally reverting back to baseline. However, qualitatively, the stool microbiome did exhibit change immediately prior to and post TD episode.

It should be noted that our study has constraints. The number of independent subjects enrolled in Study 2a and 2b was limited due to difficulties with recruitment in an active military operational setting, and a much larger cohort of individuals will be required to confirm our observations or to build accurate predictive models for susceptibility that are not at risk of over-fitting. Subjects volunteered to participate, and as such, this created a bias towards individuals who are willing to participate in survey and fecal sampling studies. Additionally, the results may be context dependent; the microbial signature that indicates protection or susceptibility to TD may not apply to non-US populations and, within US populations, the same gut microbial community may not be indicative of susceptibility or protection from TD if challenged by an environment with a different microbial milieu (e.g., TD-causing *Campylobacter* spp. in southeast Asia). All US military personnel deployed to areas at a high risk of malaria are required to take doxycycline as an antimalarial prophylactic. Doxycycline has also been used in the prevention of TD \[[@pone.0236703.ref057],[@pone.0236703.ref058]\], which may impact TD rates in our study population. We only had access to subjects while they were deployed and hence we have no control group that were on site but not taking doxycycline. Long-term use of antibiotics \[[@pone.0236703.ref059],[@pone.0236703.ref060]\] can persistently alter the gut microbiome, however, we do not have samples prior to or after deployment, and due to this cannot address the impact of doxycycline on these subjects. While this is an important issue to investigate in future studies, addressing the question of long-term effects of doxycycline goes beyond the scope of this study.

Despite these constraints, this study provides the most comprehensive longitudinal TD and microbiome analysis of personnel in a deployed, forward operating base to date. The nature of the environment ensured that subjects experienced similar conditions throughout the length of the study, including diet and food accessibility, physical activity levels, and deployment-associated stressors that would not have been easily replicated in a non-deployment scenario.

Future studies, to extend these results, should include a larger pool of independent subjects for better predictive models, metagenomic sequencing of samples to identify novel, TD-causing pathogens, and long-term studies of individuals who suffer post-TD irritable bowel syndrome or other GI disorders \[[@pone.0236703.ref061]\], for any potentially causative role related to microbial dysbiosis.

Collectively, with the caveat that these data are subjectively reported, the findings illustrate that even in a military base with a modern dining facility, good sanitation, and housing, TD is still problematic and impactful and the etiology of TD is complex, frequently associated with multiple pathogens. Our analyses of the gut microbiome provide tantalizing clues into its role in TD, with a *Ruminiclostridium* spp. associating with resistance and an uncultured Ruminococcaceae UCG-013 taxa associating with susceptibility to TD in this study, as well as an observation of disrupted microbiota several weeks before TD events (subject 33) which could serve as an indicator of susceptibility. Analyses of longitudinal studies and/or larger cohorts during travel and deployment are likely to identify strains and communities within the gut microbiome that provide resiliency or susceptibility to TD. These data could provide an important component to the treatment and prevention of TD, possibly through modulation of the gut microbiome using prebiotic, probiotic, or synbiotic methods.

Supporting information {#sec015}
======================

###### Longitudinal volatility tests of alpha and beta diversity.

QIIME2 longitudinal output is shown for observed OTUs (A), Faith's phylogenetic diversity (B), Evenness (C), Shannon (D) and Chao1 (E) alpha diversity measures, and Jaccard (F), unweighted UniFrac (G), weighted UniFrac (H), and Bray-Curtis (I) beta diversity metrics/dissimilarity.

(EPS)

###### 

Click here for additional data file.

###### Post-deployment questionnaire.

(PDF)

###### 

Click here for additional data file.

###### Taxonomy plots in QIIME2 artifact format.

This includes per-sample metadata, and can be viewed at <https://view.qiime2.org/>. For example, choose taxonomic level 3 to see the class level, and under "Sort Samples By" select "Subject", then click + to add additional sorting for "Order" and again for "ClinicalTD". Taxonomies can be toggled by clicking the colored box next to the taxa.

(QZV)

###### 

Click here for additional data file.

###### Weighted UniFrac PCoA plot of TD subjects versus adult subjects from Yatsunenko et al \[[@pone.0236703.ref041]\] in QIIME2 artifact format.

This can be viewed at <https://view.qiime2.org/>. For example, to view the data by TD subject, select "Subject" under the scatter dropdown box. Successive time points can be connected by clicking the animations tab, selecting Gradient-\>Order, Trajectory-\>Subject, and clicking the play button.

(QZV)

###### 

Click here for additional data file.

###### iPod Touch questionnaire data.

The raw data, plus a manually entered "CorrectedDate" column, are included.

(XLSX)

###### 

Click here for additional data file.

###### QIIME-compatible metadata mapping file with parsed data from the iPod questionnaire (including inferred sleep duration) included.

(TXT)

###### 

Click here for additional data file.

###### Linear mixed model results for microbial abundances versus TD category and versus self-reported GI distress levels for study 2b samples.

The anova output from lmer results, plus FDR-corrected p-values are shown.

(XLSX)

###### 

Click here for additional data file.

###### Merged QIIME-compatible metadata mapping file for samples of Yatsunenko et al and study 2b samples.

(TXT)

###### 

Click here for additional data file.

###### Summary of microbial taxonomies from prior studies which distinguish human subjects that acquired TD and those that did not.

(XLSX)

###### 

Click here for additional data file.

###### This shows the R environment used for the linear mixed model testing.

(TXT)

###### 

Click here for additional data file.
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While all of the reviewers agreed that this is an interesting and important study, the reviewers noted some issues that need to be adequately addressed to improve the manuscript presentation, data analysis, and overall rigor and quality. 

We would appreciate receiving your revised manuscript by May 24 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Brenda A Wilson, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

While all of the reviewers agreed that this is an interesting and important study, the reviewers noted some issues that need to be adequately addressed to improve the manuscript presentation, data analysis, and overall rigor and quality.

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1.    Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

3\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4\. Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

1.     Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Traveller's diarrhea is a highly important and relevant topic to military personnel and civilian traveller's alike, and there is substantial interest in determining etiology, and treatment and recovery strategies. Few studies have examined the gut microbiota as a factor in traveller's diarrhea. As such, this study will make a welcomed and important contribution to the evidence base. I congratulate the study team for conducting what was undoubtedly a difficult and time-consuming study to execute. This likely contributed to the small sample size for microbiota analyses. This is obviously a study limitation, and is readily acknowledged by the authors. I do think there are several areas where this paper could be improved, particularly in the methods which I think could be presented more clearly given the inclusion of multiple sub-studies/cohorts in the paper, and in the analyses which could be expanded. Specific comments are below.

MAJOR COMMENTS:

1\) The methods used for each study are somewhat difficult to determine (e.g., see minor comments below). Please consider separating into study 1, study 2, etc. and describing the purpose of each study, the methods used for each study, and the results for each study separately. A figure to show the different cohorts, the samples they provided, and when those samples/data were provided may be helpful. Additionally, using the same terminology to describe each study throughout the text would be helpful. Currently, it seems that active/passive surveillance, epidemiology, longitudinal, etc. are used variably and sometimes interchangeably throughout creating confusion as to which methods and results correspond to which cohort. Finally, sample size calculations are needed, or, if none, the rationale for the sample sizes within each study should be clarified.

2\) Much of the results are presented as descriptive analyses, including those generated from the most novel cohort in this study, the n=11 longitudinal cohort (e.g., Ln 412-471). To increase the impact of this important research, the authors are encouraged to consider additional analyses. For example, were there any demographic or behavioral predictors of TD in the retrospective or n=67 longitudinal study? In the n=11 cohort, considering questions such as differentially abundant taxa prior to and after TD development (in addition to throughout) in TD+ vs TD- subjects, and determining whether pre-TD composition was restored in TD+ subjects following TD would be of interest (e.g., Pop M, et al. BMC Genomics 2016;17:440; Dethlefsen and Relman, PNAS 2011;108:4554). Given the small n, perhaps using an n of 1 type approach (e.g., Vohra S et al., BMJ 2015;350:h1738) would be useful. Statements such as those made in ln 624-626 lead one to believe that some of this analysis has already been completed. If so, please consider whether those data can be more clearly identified and/or incorporated into the results.

MINOR COMMENTS:

2\) Ln 123-126: More details regarding the methods used for this cohort is needed. For example, was data extracted from medical records, if so, what data? Were stool samples collected?

3\) Ln 120-121: Suggest removing anecdotes. Shouldn't studies 1 and 2 provide data to estimate TD rates? Are there any historical data to support the statement?

4\) Ln 126-131: Please clarify if these questionnaires have been validated and/or if other published studies have used the same questions to assess incidence of TD. Given the retrospective design and that TD is more likely early in deployment, how reliable can we expect these data to be? This should be considered in the study limitations.

5\) How were TD and GI distress defined in the different study cohorts?

6\) Please include inclusion/exclusion criteria, if any, for the n=67 and n=11 cohorts.

7\) Ln 146: How were these subjects selected? If not random, this could bias results and should be considered as a limitation.

8\) Ln 158: Passive or active surveillance/ study 1 or study 2?

9\) Ln 159-162: What groups are being compared?

10\) Ln 169: More detail on the univariate analyses used is needed (e.g., type of regression, variables were included in the model, etc.). Ln 310-362 report descriptive analyses, but where are the analyses described in ln 169-172 presented?

11\) Ln 174, 208: Details regarding stool sample collection methods (e.g., who, where, how, when) are needed.

12\) Ln 323: Please define "reduced performance"

13\) Ln 474-481: Please clarify whether these SVs were differentially abundant before or after TD events or both?

14\) Ln 533: The meaning of "tolerance of disrupted peristalsis" is unclear, please clarify.

15\) Ln 550-552: Were the n=11 subjects queried as to whether they had already experienced TD prior to study enrollment? If so, this should be considered in the analysis. If not, this should be discussed as a limitation.

16\) Ln 573-574: Did the authors also consider including: Kampmann C, et al. Clin Microbiol Infect 2016;22:61 or Dicksved J et al. mBio 2014;5:e01212-14?

17\) Ln 645-646: Im not sure that the results or discussion support this statement. Suggest removing.

18\) Suggest avoiding military terminology as much as possible (e.g., operational tempo, forward operating base, etc.).

19\) Figure 6: This appears to be the first place Honduras, presumably the study site, is mentioned. Please clarify that the Honduras subjects are from the present study, and none of the Honduras data points are from the Yatsuneko study.

Reviewer \#2: The authors present an interesting study to understand the effect of traveler's diarrhea on deployed military subjects, including incident rate, identification of pathogens and changes in gut microbiome. Literature about the effects of TD on deployed personnel with regard to microbiome is limited. Results from this study begins to identify how the microbiome both effects TD and is affected by TD. This paper highlights the difficulties of conducting this type of research. Study constraints and challenges were discussed, as well as next steps to extend the results.

1\. Content: Comments made to illustrate points that are unclear or changes to address document flow/readability

Line 353-354 Including the reason for the differences in Shigella detection using plating vs non-culture method to illustrate the limitation of culture based methods would be informative.

Line 441 Transition sentence explaining reason for examining subjects 29 and 33 by sampling week would be helpful and improve document flow

Line 475 Differential SV detection was presented. State the reason for examining SVs.

Lines 496-500 Sentence long and a difficult read. Break into separate sentences (stool consistency and time points)?

Line 507 Specify the cohort being compared to the globe questionnaire is from Honduras

Lines 526-529 Is this determined from data in fig 2?

Meaning of data in parenthesis is unclear in:

• Table 1 Mean age values unclear (e.g., what do "(32.3, 34.7)" for females). Also on line 311

• Table 2 Diarrhea, median episode \# per person: 2 (1, 40)

Days experiencing diarrhea, median per person range: 3 (1, 60)

• Table 5 Mean are range: 42.3 (36.9, 47.6), 37.6 (34.7, 40.5)

Tables 4, 6 Identifying EPEC, EAEC, ETEC, STEC in legend would be helpful to not have to refer back to the text (unless not a PLOS One convention)

Figure 5 Include p-values (in legend or in text)

Figure 6 Difficult to follow. Rewrite to clarify such that the figure and legend stands on its own and referring back to the text is not necessary.

• Legend should be reformatted to have the letter 1st, then the test (e.g.: B. US subjects deployed...)

• Panel C: State that subjects are for all time points

Figure 1 Legend needs more detail describing the bottom panel with the dots showing interactions

2\. Formatting

Materials and Methods: spacing after colons in subheadings not consistent (e.g., p. 10, lines 169 and 174)

Units not consistent: h vs hour (various locations in document)

Line 98 Change followed to following

Line 286 Correct ipod to iPod

Line 266 clarify anova( )

Line 288 FDR not defined

Line 628 Correct "and- - a"

Line 183 Identification using API-20E strips mentioned, but no data presented

Lines 286-288 Rewrite to correct grammar/tense

Line 386 Is separate 5b legend here? Also in table 5 legend on line 384

Line 540 Define lower operational tempo (move from line 548)

Line 556-567 Format citations consistently. Add citation \#s individually?

Reviewer \#3: This manuscript discuss the epidemiology and changes in the associated microbiota in deployed military personnel at high risk of traveler\'s diarrhea. The information presented is appropriate to researchers interested in studying the alteration in microbiome as a causative agent for some of the prevalent disease. This topic is worthy of study and this paper makes a great start on this. The methods, data interpretation, and conclusions are appropriate. The authors themselves list the limitations of the experiments presented in the conclusion section. There were only a limited number of independent subjects enrolled in addition to this result may not apply to non-US populations due to the high variability in microbiome composition as a result of different geographic location. Acknowledging these shortcomings, the reviewer believes the manuscript stands on its own. The reviewer would like for future experiments to include the above-mentioned limitations of the present study, although this would have to be in a separate manuscript.

I just wander did the authors evaluate the effect of doxycycline as antimalarial prophylactic dose on the microbiota composition of all subjects included in this study. I think this may be responsible for some of the microbiome alteration. Finally, did the authors used negative and positive sequencing controls? It is now clearly established that reagents used in microbiome studies have readily detectable bacterial DNA (Salter BMC Biology 2014). Therefore, it is crucial to sequence reagents (and ideally, have controls at every step of samples acquisition, preservation and preparation) to control for potential contaminations

Reviewer \#4: April 7, 2020

Editor-in-Chief,

PLOS ONE

I have carefully reviewed the manuscript titled \"Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler's diarrhea" authored by Walters et al. This article is aligned with the scope of PLOS ONE Journal and provide valuable information on the relationship between long-term deployment and traveler's diarrhea (TD). TD has a significant impact on military personals and this manuscript will help guide future research in identifying potential causes of TD. To resolve underreported TD cases, authors followed a comprehensive surveillance plan among deployed military personals and to understand the etiology of TD author utilized state of art methods in conducting the microbiome analysis. However, this manuscript needs several minor revisions. Following are the concerns that need to be addressed:

Thank you

Sincerely

Akemi Wijayabahu

COMMENTS TO THE AUTHOR

General Comments:

I commend the authors for conducting a comprehensive fecal analysis for various pathogens and not limiting to gut bacteria. Also, for providing a detailed methods section. To resolve underreported TD cases, authors followed a comprehensive surveillance plan among deployed military personals and to understand the etiology of TD author utilized state of art methods in conducting the microbiome analysis.

My suggestions are to have more group-based data in the results section and to minimize the focus on case by case data. Perhaps, the authors can include case reports in the supplemental section. Additionally, the discussion section should be more focused on TD and how different bacterial taxa relates to TD. Use of Doxycycline during the deployment period is a major factor that needs to be discussed further by relating to its impact on TD, known evidence on the dysbiosis of gut microbiota, risk of resistant infections, the protective effect of Doxy on TD risk, etc.

Reference: Diptyanusa, A., Ngamprasertchai, T., & Piyaphanee, W. (2018). A review of antibiotic prophylaxis for traveler's diarrhea: past to present. Tropical diseases travel medicine and vaccines, 4(1), 1-8.

Minor Comments:

Abstract-

Page 2, line 32 -- suggest revising the methods section to include a sentence describing the microbiome analysis. I also suggest revising the structure of the abstract to separate the purpose, methods and results sections.

Page 3, lines 54-56- The authors described the impact of TD on military operations/performance but did not provide any results related to the topic. Suggest providing some evidence (Ex- duty days lost).

"These findings illustrate the complex etiology of diarrhea amongst military personnel in deployed settings and its impacts on performance."

Background-

Page 5, lines 91-93 (and page 4-5 paragraph)- It would be better if the authors can describe known evidence and research gap related to TD, then provide a specific hypothesis. In this paragraph, the author provides a good strong background on microbiota, function, and relationship to diseases/disorders in general. This paragraph needs at least some information relating to microbiota and TD.

"Thus, we hypothesize that gut microbial community composition can be a significant factor in symptomatic and sub-clinical syndromes." Relating to TD or in general any illness?

Page 5, line 100- When authors mention of "illness", does this mean any disease/disorder during deployment or just TD?

Methods-

Page 6, line 110- Maybe it would be better to include a definition for "forward deployment" within brackets/parenthesis or use a more general term (Ex- deployed to a US military base on foreign soil/Central America).

Page 6, lines 128-131- Did the questionnaire include a specific time duration? As an example, past events including signs and symptoms of diarrhea, respiratory, and febrile illnesses.........during the past 30 days or 12 months? Also, I recommend including the questionnaire in the supplemental section (or provide the referenced Table SX).

Page 8, lines 160-161- I apologize for my unfamiliarity with the word "time in theater", is this a specific room as a surgical theater? Please clarify?

Did the authors have the following baseline information? time since deployment, history of prior diarrheal infections, race, risk factors contributing to the transmission of pathogenic bacteria within the deployment site (hygienic behavior assessment, availability of resources, etc.), use of other medication (laxatives), use of probiotics (yogurt)?

Page 8, lines 165-166- How did the authors treat multi-pathogen infections (co-infections) when calculating incidence for each pathogen?

Page 9, lines 207-209- Did the authors use any kind of buffer to store the fecal samples (RNAlater)?

Page 10, lines 221-227- Suggest adding a sub-heading

Page 11, lines 239-241- Suggest including a Chao1 graph to the results section if possible

Results-

Page 15, Table 2- suggest specifying the duration of the assessment (Ex- during the past 12 months?)

Page 17, Table 3- Earlier when describing other illness, it was not clear that the symptoms were associated with diarrhea or due to unrelated illnesses. Please clarify this in the methods section/other sections.

Page 19-20, Table 4- Please provide a footnote with abbreviations and definitions

Pages 23-24- Suggest including heat maps, diversity plots and figure representing relative abundance by phyla for groups (TD+ vs TD- summarized across all participants)

Discussion-

Page 30, lines 588-591- Suggest revising the sentence as I don't see the relevance of IBD and TD the way it is presented here.

Page 31, lines 594-597- Is it possible that the changes in the gut microbiota due to doxycycline and other antimalarial prophylactics might contribute to the risk of TD? Please include past research evidence on this subject. It is possible participants taking such medication already have a disrupted gut microbiota.

Also, please briefly discuss the strengths of the study in the discussion section (controlled diet, similar physical activity levels, etc.).

Conclusion- Suggest revising the conclusion to include a summary of findings across all participants with TD compared to those without TD (or before and after TD results of individuals collectively).

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: Yes: Akemi T Wijayabahu

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236703.r002

Author response to Decision Letter 0

21 May 2020

Dear editor and reviewers,

We thank the editor and reviewers for their time and comments. Our responses to the issues raised by the editor and the reviewers are listed immediately below for our responses to questions raised by the editor, and following each question for the reviewers. Our responses are below, following the questions raised by the editor and reviewers.

Subject: PLOS ONE Decision: Revision required \[PONE-D-19-31202\] - \[EMID:fdfe19777cc69a83\]

Date: 9 Apr 2020 07:19:35 -0400

From: PLOS ONE \<<em@editorialmanager.com>\>

Reply-To: PLOS ONE \<<plosone@plos.org>\>

To: William A. Walters \<<william.walters@tuebingen.mpg.de>\>

PONE-D-19-31202

Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler\'s diarrhea

PLOS ONE

Dear Walters,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

While all of the reviewers agreed that this is an interesting and important study, the reviewers noted some issues that need to be adequately addressed to improve the manuscript presentation, data analysis, and overall rigor and quality.

We would appreciate receiving your revised manuscript by May 24 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Brenda A Wilson, Ph.D.

Academic Editor

PLOS ONE

We checked the requirements from this URL (<https://journals.plos.org/plosone/s/submission-guidelines>) as the above URLs appear to be nonfunctional, at least at the time that we were working on the revisions. I did specifically notice that we had exceeded the 300 word limit for the abstract (<https://journals.plos.org/plosone/s/submission-guidelines>\#loc-abstract) and we have made suggested modifications in the submitted revision

We have confirmed that the corresponding author, Michael Goodson, has a valid ORCID (0000-0002-5004-551X).

We have made sure that the samples are now publicly (previously private) available on the European Nucleotide Archive under project PRJEB31759.

Additional Editor Comments (if provided):

While all of the reviewers agreed that this is an interesting and important study, the reviewers noted some issues that need to be adequately addressed to improve the manuscript presentation, data analysis, and overall rigor and quality.

Journal requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

3\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4\. Thank you for stating the following in the Competing Interests section:

\"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

1\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.
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We have included an updated section regarding the Henry M. Jackson foundation. We do note that this foundation is a non-profit institution rather than a commercial enterprise, but in any case, did not have a role in this study\'s design, research, or manuscript preparation.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Partly

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

Reviewer \#4: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Traveller's diarrhea is a highly important and relevant topic to military personnel and civilian traveller's alike, and there is substantial interest in determining etiology, and treatment and recovery strategies. Few studies have examined the gut microbiota as a factor in traveller's diarrhea. As such, this study will make a welcomed and important contribution to the evidence base. I congratulate the study team for conducting what was undoubtedly a difficult and time-consuming study to execute. This likely contributed to the small sample size for microbiota analyses. This is obviously a study limitation, and is readily acknowledged by the authors. I do think there are several areas where this paper could be improved, particularly in the methods which I think could be presented more clearly given the inclusion of multiple sub-studies/cohorts in the paper, and in the analyses which could be expanded. Specific comments are below.

MAJOR COMMENTS:

1\) The methods used for each study are somewhat difficult to determine (e.g., see minor comments below). Please consider separating into study 1, study 2, etc. and describing the purpose of each study, the methods used for each study, and the results for each study separately. A figure to show the different cohorts, the samples they provided, and when those samples/data were provided may be helpful. Additionally, using the same terminology to describe each study throughout the text would be helpful. Currently, it seems that active/passive surveillance, epidemiology, longitudinal, etc. are used variably and sometimes interchangeably throughout creating confusion as to which methods and results correspond to which cohort. Finally, sample size calculations are needed, or, if none, the rationale for the sample sizes within each study should be clarified.

We have endeavored to clarify the studies in the methods. The prior passive surveillance study is now listed as study 1, and the active, follow-up study, is referred to as study 2a. The nested cohort of study 2a that provided weekly fecal samples is now study 2b. We do not feel that a figure showing the different cohorts would be beneficial since subjects in Study 1 and Study 2a only provided samples if they were ill. Subjects for the microbiome longitudinal study did provide samples and answered the e-survey on a schedule, and this is shown in Fig. 2. We have worked to clarify these details in the text to give an overview of the separate studies involved.

2\) Much of the results are presented as descriptive analyses, including those generated from the most novel cohort in this study, the n=11 longitudinal cohort (e.g., Ln 412-471). To increase the impact of this important research, the authors are encouraged to consider additional analyses. For example, were there any demographic or behavioral predictors of TD in the retrospective or n=67 longitudinal study? In the n=11 cohort, considering questions such as differentially abundant taxa prior to and after TD development (in addition to throughout) in TD+ vs TD- subjects, and determining whether pre-TD composition was restored in TD+ subjects following TD would be of interest (e.g., Pop M, et al. BMC Genomics 2016;17:440; Dethlefsen and Relman, PNAS 2011;108:4554). Given the small n, perhaps using an n of 1 type approach (e.g., Vohra S et al., BMJ 2015;350:h1738) would be useful. Statements such as those made in ln 624-626 lead one to believe that some of this analysis has already been completed. If so, please consider whether those data can be more clearly identified and/or incorporated into the results.

The reviewer is correct that a permanent disruption (i.e. an alternative stable state assumed after traveler's diarrhea disruption) or resilience in the gut microbiome, where the community returned to a prior configuration, would be of interest, particularly due to a possible explanation for long-term post-deployment IBS. Unfortunately, as you have pointed out, our ability to go beyond a descriptive analysis is limited due to the number of subjects with both multiple TD events and long-term sampling. We have noted this in the text, along with the citations regarding perturbations due to antibiotic usage.

MINOR COMMENTS:

2\) Ln 123-126: More details regarding the methods used for this cohort is needed. For example, was data extracted from medical records, if so, what data? Were stool samples collected?

We have modified the methods section to clarify the cohorts sampled in this study.

3\) Ln 120-121: Suggest removing anecdotes. Shouldn't studies 1 and 2 provide data to estimate TD rates? Are there any historical data to support the statement?

We have updated the text to remove the anecdote, and have provided historical context from military studies in central/south American countries. Unfortunately, historical data for this particular site in Honduras is not available, so this study is, as the reviewer points out, the estimate for TD rates at the Honduras site.

4\) Ln 126-131: Please clarify if these questionnaires have been validated and/or if other published studies have used the same questions to assess incidence of TD. Given the retrospective design and that TD is more likely early in deployment, how reliable can we expect these data to be? This should be considered in the study limitations.

We do agree that self-recall can have inaccuracies, and have added text to reflect this, and included the specific questionnaire as a supplemental pdf file. We've also noted a prior study that has been carried out using a recall approach and a similar questionnaire. We do think that we are capturing more cases than formal TD testing detects, as many cases are mild and unreported.

5\) How were TD and GI distress defined in the different study cohorts?

We have included definition for TD, and added that GI distress was listed as one of the options on the daily e-survey and was therefore self-reported.

6\) Please include inclusion/exclusion criteria, if any, for the n=67 and n=11 cohorts.

We have included that subjects were recruited as soon as they reported to the medical facility at the start of their deployment. If subjects volunteered for the study, the only exclusion criteria was a stay on base less than 1 month.

7\) Ln 146: How were these subjects selected? If not random, this could bias results and should be considered as a limitation.

There was no random selection. Prospective subjects were briefed on the study and contacted the study coordinator individually if they wished to participate. There was mechanisms in place to prevent coercion. For passive surveillance, individuals were enrolled when they arrived to the clinic and consented to participate. Surveys were given at the end of deployment and were voluntarily submitted. The voluntary nature of the study has been included in the text.

8\) Ln 158: Passive or active surveillance/ study 1 or study 2?

We have modified the methods section to clarify the cohorts sampled in this study.

9\) Ln 159-162: What groups are being compared?

We have changed the wording to more accurately describe the methods.

10\) Ln 169: More detail on the univariate analyses used is needed (e.g., type of regression, variables were included in the model, etc.). Ln 310-362 report descriptive analyses, but where are the analyses described in ln 169-172 presented?

We apologize, this was from an earlier iteration of the manuscript. We have decided to modify this, and the results, section for clarity. We did not analyze beyond descriptive statistics for risk factors from the post deployment surveys as the sample sizes of the cohorts were small.

11\) Ln 174, 208: Details regarding stool sample collection methods (e.g., who, where, how, when) are needed.

We have updated our methods to include the specific kit/manufacturer involved and methods for sampling/processing.

12\) Ln 323: Please define "reduced performance"

'Reduced performance' redefined as 'reduction in their ability to perform their job'.

13\) Ln 474-481: Please clarify whether these SVs were differentially abundant before or after TD events or both?

We have modified a sentence to clarify that these are all time points except for the specific time points of traveler\'s diarrhea.

14\) Ln 533: The meaning of "tolerance of disrupted peristalsis" is unclear, please clarify.

We have modified this statement for clarity-we wrote this as two distinct categories when the latter portion were examples of resistance and resilience.

15\) Ln 550-552: Were the n=11 subjects queried as to whether they had already experienced TD prior to study enrollment? If so, this should be considered in the analysis. If not, this should be discussed as a limitation.

For the active surveillance (study 2), subjects were queried about prior diarrhea or vomiting (for the prior two weeks before enrollment). Only one subject stated that they had diarrhea, subject 29. We have modified the text to account for this.

16\) Ln 573-574: Did the authors also consider including: Kampmann C, et al. Clin Microbiol Infect 2016;22:61 or Dicksved J et al. mBio 2014;5:e01212-14?

Campylobacter spp. were not detected as TD-causing agents in our study, but they are significant contributors to the disease, particularly in southeast Asia. We\'ve added these results to the discussion with these caveats.

17\) Ln 645-646: Im not sure that the results or discussion support this statement. Suggest removing.

We have removed this statement, and emphasized that further study is required to determine the potential of modulating the microbiome to effect TD.

18\) Suggest avoiding military terminology as much as possible (e.g., operational tempo, forward operating base, etc.).

We take the reviewer's point and have tried to do so as much as possible. Some military terminology is unavoidable because of the nature of the subject's environment.

19\) Figure 6: This appears to be the first place Honduras, presumably the study site, is mentioned. Please clarify that the Honduras subjects are from the present study, and none of the Honduras data points are from the Yatsuneko study.

We have modified the manuscript to emphasize that the subjects are US warfighters deployed to Honduras. We have also changed the legend of Figure 6 to clarify which data are from the current study.

Reviewer \#2: The authors present an interesting study to understand the effect of traveler's diarrhea on deployed military subjects, including incident rate, identification of pathogens and changes in gut microbiome. Literature about the effects of TD on deployed personnel with regard to microbiome is limited. Results from this study begins to identify how the microbiome both effects TD and is affected by TD. This paper highlights the difficulties of conducting this type of research. Study constraints and challenges were discussed, as well as next steps to extend the results.

1\. Content: Comments made to illustrate points that are unclear or changes to address document flow/readability

Line 353-354 Including the reason for the differences in Shigella detection using plating vs non-culture method to illustrate the limitation of culture based methods would be informative.

We have added a sentence to address this comment.

Line 441 Transition sentence explaining reason for examining subjects 29 and 33 by sampling week would be helpful and improve document flow

We have added a sentence clarifying why we focused on subject 29 and 33.

Line 475 Differential SV detection was presented. State the reason for examining SVs.

We\'ve added a sentence to address this.

Lines 496-500 Sentence long and a difficult read. Break into separate sentences (stool consistency and time points)?

We separated this sentence and modified it to improve flow.

Line 507 Specify the cohort being compared to the globe questionnaire is from Honduras

We have changed the text to highlight this.

Lines 526-529 Is this determined from data in fig 2?

Yes, and reference to Fig. 2 added.

Meaning of data in parenthesis is unclear in:

• Table 1 Mean age values unclear (e.g., what do "(32.3, 34.7)" for females). Also on line 311

This is the a 95% confidence interval, the table text was modified to reflect this.

• Table 2 Diarrhea, median episode \# per person: 2 (1, 40)

Days experiencing diarrhea, median per person range: 3 (1, 60)

These are the lowest and highest values, respectively and we have changed the table to 'min, max'.

• Table 5 Mean are range: 42.3 (36.9, 47.6), 37.6 (34.7, 40.5)

We have clarified that these are 95% CI in the text.

Tables 4, 6 Identifying EPEC, EAEC, ETEC, STEC in legend would be helpful to not have to refer back to the text (unless not a PLOS One convention)

We have added the abbreviation descriptions below Tables 4 and 6.

Figure 5 Include p-values (in legend or in text)

We have added the FDR-corrected p-values to the figure text.

Figure 6 Difficult to follow. Rewrite to clarify such that the figure and legend stands on its own and referring back to the text is not necessary.

• Legend should be reformatted to have the letter 1st, then the test (e.g.: B. US subjects deployed...)

• Panel C: State that subjects are for all time points

Figure 6 legend has been modified to incorporate the reviewer's comments and to improve clarity.

Figure 1 Legend needs more detail describing the bottom panel with the dots showing interactions

We have modified both the figure and the legend texts (1 and 6) to address the issues with clarity raised here.

2\. Formatting

Materials and Methods: spacing after colons in subheadings not consistent (e.g., p. 10, lines 169 and 174)

We have made the subheadings consistent.

Units not consistent: h vs hour (various locations in document)

We changed all reference to hours to 'h'

Line 98 Change followed to following

We feel this would change the meaning of the sentence, so we modified the sentence instead.

Line 286 Correct ipod to iPod

Corrected.

Line 266 clarify anova( )

We have expanded the sentence for clarity.

Line 288 FDR not defined

We have added \'Benjamini-Hochberg\' to indicate the type of correction.

Line 628 Correct "and- - a"

Corrected.

Line 183 Identification using API-20E strips mentioned, but no data presented

We have modified the text to indicate that the strips were used to identify Salmonella and Shigella from bacterial cultures as indicated in the Results section and in Tables 4 and 6.

Lines 286-288 Rewrite to correct grammar/tense

This explains the linear mixed model description and we feel changing the 'W' to lower case clarifies this, as it is used in line 261 of the original submission.

Line 386 Is separate 5b legend here? Also in table 5 legend on line 384

Yes, that was an oversight on our part. We have deleted the legend originally on Line 386.

Line 540 Define lower operational tempo (move from line 548)

This is a military term. We have attempted to clarify this in the text.

Line 556-567 Format citations consistently. Add citation \#s individually?

We have altered this section to have consistent citations with the rest of the document, and separated the citations to be part of the individual relevant sentences.

Reviewer \#3: This manuscript discuss the epidemiology and changes in the associated microbiota in deployed military personnel at high risk of traveler\'s diarrhea. The information presented is appropriate to researchers interested in studying the alteration in microbiome as a causative agent for some of the prevalent disease. This topic is worthy of study and this paper makes a great start on this. The methods, data interpretation, and conclusions are appropriate. The authors themselves list the limitations of the experiments presented in the conclusion section. There were only a limited number of independent subjects enrolled in addition to this result may not apply to non-US populations due to the high variability in microbiome composition as a result of different geographic location. Acknowledging these shortcomings, the reviewer believes the manuscript stands on its own. The reviewer would like for future experiments to include the above-mentioned limitations of the present study, although this would have to be in a separate manuscript.

I just wander did the authors evaluate the effect of doxycycline as antimalarial prophylactic dose on the microbiota composition of all subjects included in this study. I think this may be responsible for some of the microbiome alteration.

No, we did not. We take the reviewer\'s point, but all personnel are required to take doxycycline as a prophylactic antimalarial. We did not have the ability to have a control group that did not take doxycycline and have added statements to address this. We do think this would make an excellent follow up study.

Finally, did the authors used negative and positive sequencing controls? It is now clearly established that reagents used in microbiome studies have readily detectable bacterial DNA (Salter BMC Biology 2014). Therefore, it is crucial to sequence reagents (and ideally, have controls at every step of samples acquisition, preservation and preparation) to control for potential contaminations

The reviewer has raised a good point, and we have added comments in the methods section regarding negative and positive controls.

Reviewer \#4: April 7, 2020

Editor-in-Chief,

PLOS ONE

I have carefully reviewed the manuscript titled \"Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler's diarrhea" authored by Walters et al. This article is aligned with the scope of PLOS ONE Journal and provide valuable information on the relationship between long-term deployment and traveler's diarrhea (TD). TD has a significant impact on military personals and this manuscript will help guide future research in identifying potential causes of TD. To resolve underreported TD cases, authors followed a comprehensive surveillance plan among deployed military personals and to understand the etiology of TD author utilized state of art methods in conducting the microbiome analysis. However, this manuscript needs several minor revisions. Following are the concerns that need to be addressed:

Thank you

Sincerely

Akemi Wijayabahu

COMMENTS TO THE AUTHOR

General Comments:

I commend the authors for conducting a comprehensive fecal analysis for various pathogens and not limiting to gut bacteria. Also, for providing a detailed methods section. To resolve underreported TD cases, authors followed a comprehensive surveillance plan among deployed military personals and to understand the etiology of TD author utilized state of art methods in conducting the microbiome analysis.

My suggestions are to have more group-based data in the results section and to minimize the focus on case by case data. Perhaps, the authors can include case reports in the supplemental section.

We thank the reviewer/editor for their comments. We wanted to strike a balance in our analyses of the data: on the one hand we attempted to analyze grouped data for microbial markers of susceptibility or resilience to TD; and on the other hand, focus on those subjects that experienced multiple TD episodes to look for microbial differences in abundance before and after, as well as to see if there were any indicators of TD prior to it. As we noted, there were some shortcomings in the data collection which meant that these data were not available for every subject. We believe we have presented data that get at the original questions we were posing. However, we are very proud of our data set and have provided links and tools for the readers to explore the data as they see fit. As you can imagine, with the nature of the subjects in this study, there are certain restrictions on which data we are allowed to publicly release, enforced by our IRB and the Unit Commanders. We have made available everything we have been allowed to.

Additionally, the discussion section should be more focused on TD and how different bacterial taxa relates to TD.

We have expanded our discussion to incorporate the reviewer's suggestion.

Use of Doxycycline during the deployment period is a major factor that needs to be discussed further by relating to its impact on TD, known evidence on the dysbiosis of gut microbiota, risk of resistant infections, the protective effect of Doxy on TD risk, etc.

Reference: Diptyanusa, A., Ngamprasertchai, T., & Piyaphanee, W. (2018). A review of antibiotic prophylaxis for traveler's diarrhea: past to present. Tropical diseases travel medicine and vaccines, 4(1), 1-8.

Our sampling did not allow us to determine if doxycycline affected the subject's microbiome or their susceptibility to diarrhea, since all personnel are required to take doxycycline as a prophylactic antimalarial when deployed to locations where the risk of malaria is high. We have expanded our discussion to address the reviewer's points, but do not feel that we can comment on any risks associated with prophylactic doxycycline administration since it is outside the scope of this study.

Minor Comments:

Abstract-

Page 2, line 32 -- suggest revising the methods section to include a sentence describing the microbiome analysis. I also suggest revising the structure of the abstract to separate the purpose, methods and results sections.

We appreciate the reviewers' suggestion and have added a sentence describing microbiome methods. We also modified the abstract. However, because of the multi-faceted nature of the project we feel that separating the sections in the abstracts would result in confusion and would prefer to have the methods and results of each part of the project follow each other.

Page 3, lines 54-56- The authors described the impact of TD on military operations/performance but did not provide any results related to the topic. Suggest providing some evidence (Ex- duty days lost).

"These findings illustrate the complex etiology of diarrhea amongst military personnel in deployed settings and its impacts on performance."

We have added a statement to the first sentence of the abstract. Also we go into detail in the Introduction and the Results, so did not want to go into too much depth about it in the abstract, but we state that those data were collected.

Background-

Page 5, lines 91-93 (and page 4-5 paragraph)- It would be better if the authors can describe known evidence and research gap related to TD, then provide a specific hypothesis. In this paragraph, the author provides a good strong background on microbiota, function, and relationship to diseases/disorders in general. This paragraph needs at least some information relating to microbiota and TD.

"Thus, we hypothesize that gut microbial community composition can be a significant factor in symptomatic and sub-clinical syndromes." Relating to TD or in general any illness?

We agree with the reviewers comments and have added to this section of the introduction to address their concerns.

Page 5, line 100- When authors mention of "illness", does this mean any disease/disorder during deployment or just TD?

This refers to any illness during deployment, but we are focusing on those reporting TD.

Methods-

Page 6, line 110- Maybe it would be better to include a definition for "forward deployment" within brackets/parenthesis or use a more general term (Ex- deployed to a US military base on foreign soil/Central America).

We take the reviewer's point. 'Forward Operating Base (FOB)' is the correct military description of this type of base. It is the equivalent of 'frontline' or 'in harm's way' but we are not sure that these provide a better description. We have added 'frontline' to the description.

Page 6, lines 128-131- Did the questionnaire include a specific time duration? As an example, past events including signs and symptoms of diarrhea, respiratory, and febrile illnesses.........during the past 30 days or 12 months? Also, I recommend including the questionnaire in the supplemental section (or provide the referenced Table SX).

The questionnaires described the time during their deployment and deployment durations varied, as well as symptoms and duration of diseases. We have added the pdf of the survey as a supplemental file.

Page 8, lines 160-161- I apologize for my unfamiliarity with the word "time in theater", is this a specific room as a surgical theater? Please clarify?

We apologize, this is military nomenclature. To clarify, we have changed it to 'deployment duration.'

Did the authors have the following baseline information? time since deployment, history of prior diarrheal infections, race,. risk factors contributing to the transmission of pathogenic bacteria within the deployment site (hygienic behavior assessment, availability of resources, etc.)

use of other medication (laxatives), use of probiotics (yogurt)?

These are all great points. Unfortunately we do not have those data. We mention that it is a well-appointed base in the discussion's first sentence , but we did not detect significance with self-reported (iPod survey) behavior. As an example, surprisingly, Lactobacillus is frequently higher in subjects who are recording zero yogurt intake than those who are reporting yogurt consumption, and for those who recorded consumption, there was not a positive trend with increased consumption. The available metadata are incorporated into the supplemental visualization artifacts, and we've added text to better explain how to examine these data.

Page 8, lines 165-166- How did the authors treat multi-pathogen infections (co-infections) when calculating incidence for each pathogen?

Incidence of TD was calculated by a positive detection of any pathogen, so multi-pathogen detection was counted as a single event in the incidence. Numbers were too low to calculate individual pathogen incidences. The data show the number and percentages of tested stools that were multi-pathogen with 2-6 pathogens detected. The clinical incidence is likely much higher than our reported incidence, but we only received reports and samples of more severe cases and thus lower numbers. Mild TD is commonly under-reported.

Page 9, lines 207-209- Did the authors use any kind of buffer to store the fecal samples (RNAlater)?

No, it was immediately frozen at -80 degrees C and was maintained at that temperature until sample processing.

Page 10, lines 221-227- Suggest adding a sub-heading

Sub-heading added.

Page 11, lines 239-241- Suggest including a Chao1 graph to the results section if possible

We calculated Chao1 alpha diversity for the microbiome data and added text (and modified figure S1) to reflect this. Unfortunately, as with the other alpha diversity tests, there were not significant results.

Results-

Page 15, Table 2- suggest specifying the duration of the assessment (Ex- during the past 12 months?)

This was the end-of-deployment questionnaire described in the Methods. The length of deployment varied.

Page 17, Table 3- Earlier when describing other illness, it was not clear that the symptoms were associated with diarrhea or due to unrelated illnesses. Please clarify this in the methods section/other sections.

We collected data on any illness, as described in the methods, but we focused on illnesses associated with diarrhea in the Results and Table 3. We have added text to the results to clarify this.

Page 19-20, Table 4- Please provide a footnote with abbreviations and definitions

We have added definitions as a footnote to Tables 4 and 6.

Pages 23-24- Suggest including heat maps, diversity plots and figure representing relative abundance by phyla for groups (TD+ vs TD- summarized across all participants)

We did generate heatmaps of relative abundances during this process, however, they show an uninteresting result-most of the samples cluster by subject, including the specific time points of traveler\'s diarrhea. Collapsing the data into averages (i.e., first averaging a subject\'s time points to a subject average, and then averaging the groups that acquired TD versus those that did not) is possible, however, we think a lot of the data could be explored (at different taxonomic levels, or with different aspects of the metadata) via the QIIME2 artifact visualization files, which can be viewed directly in a browser without special software. We\'ve added some details about how the reader can explore these data to the text to facilitate this.

Discussion-

Page 30, lines 588-591- Suggest revising the sentence as I don't see the relevance of IBD and TD the way it is presented here.

We were trying to provide the reader with as much information as we could find regarding Ruminococcaceae UCG-013 and TD and human GI issues. We have altered the text to reflect this, rather than insinuating a causal relationship.

Page 31, lines 594-597- Is it possible that the changes in the gut microbiota due to doxycycline and other antimalarial prophylactics might contribute to the risk of TD? Please include past research evidence on this subject. It is possible participants taking such medication already have a disrupted gut microbiota.

As we discussed above, our sampling did not allow us to determine if doxycycline affected the subject's microbiome or their susceptibility to diarrhea. We did not have the ability to have a control group that did not take doxycycline since all personnel are required to take doxycycline as a prophylactic antimalarial when deployed to locations where the risk of malaria is high. We have expanded our discussion to address the reviewer's points.

Also, please briefly discuss the strengths of the study in the discussion section (controlled diet, similar physical activity levels, etc.).

We thank the reviewer for the opportunity to highlight the strengths of this study. We are extremely proud of it and it is the result of many years of hard work and negotiation with Base Commanders. We have added a brief discussion of the study's strengths to the Discussion.

Conclusion- Suggest revising the conclusion to include a summary of findings across all participants with TD compared to those without TD (or before and after TD results of individuals collectively).

We thank the reviewer for the suggestion. We have noted the commonalities that we detected quantitatively or observed in the longitudinal data.

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.
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Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler\'s diarrhea

PLOS ONE

Dear Dr. Goodson,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All four reviewers and I are in agreement that the manuscript is much improved. Reviewers 2 and 4 have a few minor, helpful suggestions that should be incorporated into a revised document.

Please submit your revised manuscript by Aug 15 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Brenda A Wilson, Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

Reviewer \#3: All comments have been addressed

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: (No Response)

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors are congratulated for their execution and presentation of this important study. All of my previous comments have been satisfactorily addressed. Only 2 minor comments:

Abstract: Please add a statement describing the relevant results that support the statement "...and its impact on job performance".

Discussion states "Our results are consistent with these prior observations, as we detect no differences for alpha diversity between TD+ and TD- subjects. It should be emphasized that while our results are statistically significant, the number of independent samples are small (N=4 TD- subjects, N=7 TD+ subjects)." Should the second sentence read "not statistically significant"?

Reviewer \#2: (No Response)

Reviewer \#3: Thank you for the authors for addressing all my comments. the manuscript now is accepted from my side with no further comments or modification.

Reviewer \#4: Dear authors,

Thank you for being responsive to my recommendations and for the clarifications. I do not have any major concerns for the revised manuscript. It is much clearer and easier to understand.

Best wishes,

Akemi W.

Minor Comments:

Comment 1, Page 2-- Suggest revising the following sentence to include explanations for each of the abbreviations that are mentioned for the first time.

Suggested revision: "We conducted a passive surveillance study of all cases of diarrhea reporting to the medical unit with 152 total cases and a similar pattern of etiology with 52/152 enteroaggregative E. coli (EAEC), 50/152 enteroinvasive E. coli (EIEC), and 35/152 enteropathogenic E. coli (EPEC) as the most prevalent pathogens detected, and ......"

Introduction-

Comment 2, Page 5- Evidence related to microbiome and TD is not sufficient, the research gap not identified, and the hypothesis is still not specific for the current research.

Of note, David et al, 2015 was the only study cited. Please consider including additional literature evidence on the relationship between microbiome and TD

Comment 3, Page 5- recommend clarifying what "illness" is in the manuscript.

Suggested revision: "After enrollment and collection of baseline samples, subjects were contacted weekly to assess the presence of any ailment specifically diarrheal diseases and if ill, ...."

Discussion-

Comment 4-Should it be just recall bias?

Suggested revision: "Similarly, questionnaires performed at the end of a person's deployment may not accurately capture what they experienced because of recall bias."

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: **Yes: **Akemi T Wijayabahu

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236703.r004
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Reviewer \#1: The authors are congratulated for their execution and presentation of this important study. All of my previous comments have been satisfactorily addressed. Only 2 minor comments:

We thank the reviewer for their kind words and for their comments.

Abstract: Please add a statement describing the relevant results that support the statement "...and its impact on job performance".

We have added results to support this statement, and modified the abstract to keep it within the 300 word limit.

Discussion states "Our results are consistent with these prior observations, as we detect no differences for alpha diversity between TD+ and TD- subjects. It should be emphasized that while our results are statistically significant, the number of independent samples are small (N=4 TD- subjects, N=7 TD+ subjects)." Should the second sentence read "not statistically significant"?

We thank the reviewer for this change. We agree that for the results described in this paragraph should be changed to 'not statistically significant'. We also discuss our small sample size when we comment on statistically significant results later in the Discussion.

Reviewer \#2: (No Response)

Reviewer \#3: Thank you for the authors for addressing all my comments. the manuscript now is accepted from my side with no further comments or modification.

We thank the reviewer for their time and effort.

Reviewer \#4: Dear authors,

Thank you for being responsive to my recommendations and for the clarifications. I do not have any major concerns for the revised manuscript. It is much clearer and easier to understand.

Best wishes,

Akemi W.

We thank you for your comments and suggestions.

Minor Comments:

Comment 1, Page 2-- Suggest revising the following sentence to include explanations for each of the abbreviations that are mentioned for the first time.

Suggested revision: "We conducted a passive surveillance study of all cases of diarrhea reporting to the medical unit with 152 total cases and a similar pattern of etiology with 52/152 enteroaggregative E. coli (EAEC), 50/152 enteroinvasive E. coli (EIEC), and 35/152 enteropathogenic E. coli (EPEC) as the most prevalent pathogens detected, and ......"

We have added explanations for each of the abbreviations as suggested by the reviewer, and modified the abstract to keep it within the 300 word limit.

Introduction-

Comment 2, Page 5- Evidence related to microbiome and TD is not sufficient, the research gap not identified, and the hypothesis is still not specific for the current research.

Of note, David et al, 2015 was the only study cited. Please consider including additional literature evidence on the relationship between microbiome and TD

We thank the reviewer for these inputs.

We have added additional literature references supporting a relationship between the gut microbiome and TD. We delve into these further in the Discussion where we compare these papers to our results, and so did not feel that we should repeat an in-depth summary of the literature here, other than providing a broad summary of their results.

We have made the hypothesis specific for the current research by adding 'can contribute to susceptibility or resilience to TD' to the final sentence of the paragraph.

We have further identified the research gap at the beginning of the next paragraph by restating why a better understanding of how microbial community composition affects military personnel experiencing diarrhea during deployment is important.

Comment 3, Page 5- recommend clarifying what "illness" is in the manuscript.

Suggested revision: "After enrollment and collection of baseline samples, subjects were contacted weekly to assess the presence of any ailment specifically diarrheal diseases and if ill, ...."

We have added clarification based on the reviewers suggestion.

Discussion-

Comment 4-Should it be just recall bias?

Suggested revision: "Similarly, questionnaires performed at the end of a person's deployment may not accurately capture what they experienced because of recall bias."

Yes, we agree. We changed the sentence to the reviewer's suggestion.
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Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler\'s diarrhea

PONE-D-19-31202R2

Dear Dr. Goodson,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Brenda A Wilson, Ph.D.

Academic Editor

PLOS ONE
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PONE-D-19-31202R2

Epidemiology and associated microbiota changes in deployed military personnel at high risk of traveler\'s diarrhea

Dear Dr. Goodson:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Brenda A Wilson

Academic Editor

PLOS ONE
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